Patrick C. Walsh | Academic Influence

Patrick C. Walsh's AcademicInfluence.com Rankings

Patrick C. Walsh

Medical

#116

World Rank

#187

Historical Rank

#61

USA Rank

Urology

#1

World Rank

#1

Historical Rank

#1

USA Rank

Surgery

#4

World Rank

#8

Historical Rank

#2

USA Rank

medical Degrees

Patrick C. Walsh

Philosophy

#1458

World Rank

#2652

Historical Rank

#589

USA Rank

Logic

#210

World Rank

#454

Historical Rank

#95

USA Rank

philosophy Degrees

Download Badge

Medical
Philosophy

Patrick C. Walsh's Degrees

Bachelors Biology University of California, Berkeley

Similar Degrees You Can Earn

Best Online Bachelor's in Biology 2025

Why Is Patrick C. Walsh Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Patrick C. Walsh is an American urologist, researcher and writer, best known for developing "the anatomic approach to radical prostatectomy", involving nerve-sparing techniques which reduced the likelihood of impotence and urinary incontinence. He authored The Prostate: A Guide for Men and the Women Who Love Them and Dr. Patrick Walsh's Guide to Surviving Prostate Cancer.

(See a Problem?)

Patrick C. Walsh's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Natural history of progression after PSA elevation following radical prostatectomy. (1999) (2472)
The development of human benign prostatic hyperplasia with age. (1984) (2146)
Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. (1997) (1884)
Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. (1994) (1800)
Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. (2005) (1258)
The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. (1993) (1237)
Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. (1998) (1176)
Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. (1992) (1120)
Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium. (2002) (1072)
Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. (2001) (1042)
American Cancer Society guidelines for the early detection of cancer. (2002) (1041)
Radical prostatectomy with preservation of sexual function: Anatomical and pathological considerations (1983) (1000)
NCCN clinical practice guidelines in oncology: prostate cancer. (2010) (971)
The effect of finasteride in men with benign prostatic hyperplasia. (1992) (965)
Radical prostatectomy versus watchful waiting in early prostate cancer. (2005) (954)
Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24 (2007) (904)
The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia (1998) (863)
Prostate cancer. Clinical practice guidelines in oncology. (2007) (839)
Impotence following radical prostatectomy: insight into etiology and prevention. (1982) (829)
Mendelian inheritance of familial prostate cancer. (1992) (803)
Major Susceptibility Locus for Prostate Cancer on Chromosome 1 Suggested by a Genome-Wide Search (1996) (801)
Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. (2003) (799)
Correlation of pathologic findings with progression after radical retropubic prostatectomy (1993) (734)
Patient-reported urinary continence and sexual function after anatomic radical prostatectomy. (2000) (678)
Cancer control and quality of life following anatomical radical retropubic prostatectomy: results at 10 years. (1994) (669)
Evidence for a prostate cancer susceptibility locus on the X chromosome. (1998) (620)
Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy. (2008) (613)
Hereditary prostate cancer: epidemiologic and clinical features. (1993) (605)
Predicting 15-year prostate cancer specific mortality after radical prostatectomy. (2011) (600)
Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. (2000) (598)
Prostate-specific antigen after anatomic radical retropubic prostatectomy. Patterns of recurrence and cancer control. (1997) (596)
Prostate specific antigen in the staging of localized prostate cancer: influence of tumor differentiation, tumor volume and benign hyperplasia. (1990) (594)
Prediction of progression following radical prostatectomy. A multivariate analysis of 721 men with long-term follow-up. (1996) (577)
Serum PSA after anatomic radical prostatectomy. The Johns Hopkins experience after 10 years. (1993) (574)
Natural History of Progression After PSA Elevation Following Radical Prostatectomy (1999) (568)
Germline mutations in HOXB13 and prostate-cancer risk. (2012) (555)
Prostate specific antigen in the preoperative and postoperative evaluation of localized prostatic cancer treated with radical prostatectomy. (1988) (541)
Risk of fracture after androgen deprivation for prostate cancer. (2005) (531)
Family history and the risk of prostate cancer (1990) (524)
Germline mutations in the ribonuclease L gene in families showing linkage with HPC1 (2002) (523)
Hypermethylation of CpG Islands in Primary and Metastatic Human Prostate Cancer (2004) (513)
Familial incomplete male pseudohermaphroditism, type 2. Decreased dihydrotestosterone formation in pseudovaginal perineoscrotal hypospadias. (1974) (503)
Sexual function following radical prostatectomy: influence of preservation of neurovascular bundles. (1991) (500)
Updated nomogram to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy Gleason score (Partin tables) based on cases from 2000 to 2005. (2007) (487)
Anatomic radical prostatectomy: evolution of the surgical technique. (1998) (476)
Active surveillance program for prostate cancer: an update of the Johns Hopkins experience. (2011) (432)
Impact of anatomical radical prostatectomy on urinary continence. (1991) (427)
The induction of prostatic hypertrophy in the dog with androstanediol. (1976) (420)
Homozygous deletion and frequent allelic loss of chromosome 8p22 loci in human prostate cancer. (1993) (416)
Precise localization of the autonomic nerves from the pelvic plexus to the corpora cavernosa: a detailed anatomical study of the adult male pelvis. (1985) (407)
Evaluation of serum prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastases. (1994) (399)
Germline mutations and sequence variants of the macrophage scavenger receptor 1 gene are associated with prostate cancer risk (2002) (395)
Implication of cell kinetic changes during the progression of human prostatic cancer. (1995) (391)
The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group. (1998) (375)
Prostate cancer, Version 3.2012: featured updates to the NCCN guidelines. (2012) (358)
An updated prostate cancer staging nomogram (Partin tables) based on cases from 2006 to 2011 (2013) (346)
Influence of capsular penetration on progression following radical prostatectomy: a study of 196 cases with long-term followup. (1993) (339)
Common sequence variants on 2p15 and Xp11.22 confer susceptibility to prostate cancer (2008) (337)
Anatomical extent of lymph node dissection: impact on men with clinically localized prostate cancer. (2004) (335)
Is tumor volume an independent predictor of progression following radical prostatectomy? A multivariate analysis of 185 clinical stage B adenocarcinomas of the prostate with 5 years of followup. (1993) (331)
Comparison of percent free PSA, PSA density, and age-specific PSA cutoffs for prostate cancer detection and staging. (2000) (326)
The effect of nafarelin acetate, a luteinizing-hormone-releasing hormone agonist, on benign prostatic hyperplasia. (1987) (325)
An anatomical approach to the surgical management of the dorsal vein and Santorini's plexus during radical retropubic surgery. (1979) (323)
Prognostic significance of Gleason score 3+4 versus Gleason score 4+3 tumor at radical prostatectomy. (2000) (322)
The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group. (2002) (319)
Quality of life after radical prostatectomy or watchful waiting. (2003) (299)
Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer: a multi-institutional update. (1997) (299)
Radical Surgery for Prostatic Cancer (1980) (298)
Variations in morbidity after radical prostatectomy. (2002) (296)
Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. (2005) (295)
Nonpalpable stage T1c prostate cancer: prediction of insignificant disease using free/total prostate specific antigen levels and needle biopsy findings. (1998) (293)
A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. (2003) (293)
Era specific biochemical recurrence-free survival following radical prostatectomy for clinically localized prostate cancer. (2001) (286)
Localized Prostate Cancer (2007) (280)
Expectant management of prostate cancer with curative intent: an update of the Johns Hopkins experience. (2007) (272)
Pathological factors that influence prognosis in stage A prostatic cancer: the influence of extent versus grade. (1981) (272)
Comparison of spontaneous and experimentally induced canine prostatic hyperplasia. (1979) (272)
Two genome-wide association studies of aggressive prostate cancer implicate putative prostate tumor suppressor gene DAB2IP. (2007) (271)
Hedgehog signalling in prostate regeneration, neoplasia and metastasis. (2005) (267)
Prognosis of untreated stage A1 prostatic carcinoma: a study of 94 cases with extended followup. (1986) (258)
Immunohistochemical study of androgen receptors in metastatic prostate cancer. Comparison of receptor content and response to hormonal therapy (1991) (254)
Estimation of prostatic growth using serial prostate-specific antigen measurements in men with and without prostate disease. (1992) (254)
Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. (2003) (250)
Results of conservative management of clinically localized prostate cancer. (1994) (249)
Immunohistochemical localization of nitric oxide synthase in the autonomic innervation of the human penis. (1993) (248)
Neuroanatomical approach to radical cystoprostatectomy with preservation of sexual function. (1987) (244)
Anatomic radical retropubic prostatectomy (2005) (242)
Radical prostatectomy and cystoprostatectomy with preservation of potency. Results using a new nerve-sparing technique. (1984) (233)
Prognostic Gleason grade grouping: data based on the modified Gleason scoring system (2013) (233)
Expectant management of nonpalpable prostate cancer with curative intent: preliminary results. (2002) (231)
The natural history of metastatic progression in men with prostate‐specific antigen recurrence after radical prostatectomy: long‐term follow‐up (2012) (228)
Serum prostate specific antigen is a strong predictor of future prostate growth in men with benign prostatic hyperplasia. PROSCAR long-term efficacy and safety study. (2000) (224)
Serum LH and FSH during sexual maturation in the male rat: effect of castration and cryptorchidism. (1971) (222)
A germline DNA polymorphism enhances alternative splicing of the KLF6 tumor suppressor gene and is associated with increased prostate cancer risk. (2005) (220)
A decision analysis of alternative treatment strategies for clinically localized prostate cancer. (1993) (214)
Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council trial. The Medical Research Council Prostate Cancer Working Party Investigators Group. (1997) (210)
Clinical and experimental studies of benign prostatic hyperplasia. (1990) (207)
Prostatic evaluation by transrectal sonography with histopathologic correlation: the echopenic appearance of early carcinoma. (1986) (203)
Chemoprevention of prostate cancer. (2010) (202)
Long-term results of radiation therapy for prostate cancer recurrence following radical prostatectomy. (1998) (200)
Hormonal Therapy of Prostatic Cancer (1980) (195)
HOXB13 is a susceptibility gene for prostate cancer: results from the International Consortium for Prostate Cancer Genetics (ICPCG) (2012) (186)
Germline Mutations in ATM and BRCA1/2 Distinguish Risk for Lethal and Indolent Prostate Cancer and are Associated with Early Age at Death. (2017) (185)
The rat as a model for the study of penile erection. (1989) (183)
Use of repeat sextant and transition zone biopsies for assessing extent of prostate cancer. (1997) (181)
Validation of Partin tables for predicting pathological stage of clinically localized prostate cancer. (2000) (179)
Influence of age and endocrine factors on the volume of benign prostatic hyperplasia. (1991) (179)
Selection of men at high risk for disease recurrence for experimental adjuvant therapy following radical prostatectomy. (1995) (178)
Nerve sparing radical prostatectomy: effects of hemostatic energy sources on the recovery of cavernous nerve function in a canine model. (2004) (177)
Prospective evaluation of men with stage T1C adenocarcinoma of the prostate. (1997) (177)
Death in patients with recurrent prostate cancer after radical prostatectomy: prostate-specific antigen doubling time subgroups and their associated contributions to all-cause mortality. (2007) (177)
Radical prostatectomy for localized prostate cancer provides durable cancer control with excellent quality of life: a structured debate. (2000) (176)
Radical prostatectomy with preservation of sexual function: pathological findings in the first 100 cases. (1985) (175)
Cancer surveillance series: interpreting trends in prostate cancer--part I: evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates. (2000) (174)
Prostate-specific antigen as a marker for prostatic cancer: a monoclonal and a polyclonal immunoassay compared. (1987) (174)
Evidence for two independent prostate cancer risk–associated loci in the HNF1B gene at 17q12 (2008) (174)
Correlation of clinical stage, serum prostatic acid phosphatase and preoperative Gleason grade with final pathological stage in 275 patients with clinically localized adenocarcinoma of the prostate. (1987) (172)
Influence of radical prostatectomy on serum hormone levels. (1998) (171)
Relationship Between Perineural Tumor Invasion on Needle Biopsy and Radical Prostatectomy Capsular Penetration in Clinical Stage B Adenocarcinoma of the Prostate (1993) (171)
Potency following radical prostatectomy with wide unilateral excision of the neurovascular bundle. (1987) (170)
Microsatellite mutation (CAG24-->18) in the androgen receptor gene in human prostate cancer. (1994) (170)
The epidemiology of prostate cancer in Jamaica. (1998) (170)
Local recurrence and survival following nerve sparing radical cystoprostatectomy for bladder cancer: 10-year followup. (1996) (170)
Comparison of magnetic resonance imaging and ultrasonography in staging early prostate cancer. Results of a multi-institutional cooperative trial. (1991) (169)
Gleason score 6 adenocarcinoma: should it be labeled as cancer? (2012) (169)
Tissue content of dihydrotestosterone in human prostatic hyperplasis is not supranormal. (1983) (168)
Radical perineal prostatectomy for clinical stage B2 carcinoma of the prostate. (1982) (166)
Clinical and cost impact of second-opinion pathology. Review of prostate biopsies prior to radical prostatectomy. (1996) (166)
Impotence Following Radical Prostatectomy: Insight into Etiology and Prevention. (1982) (165)
Correlation of Postoperative Pain to Quality of Recovery in the Immediate Postoperative Period (2005) (164)
Morphometric measurement of tumor volume and per cent of gland involvement as predictors of pathological stage in clinical stage B prostate cancer. (1989) (163)
Suspected local recurrence after radical prostatectomy: endorectal coil MR imaging. (2005) (162)
6-Month Androgen Suppression Plus Radiation Therapy vs Radiation Therapy Alone for Patients With Clinically Localized Prostate Cancer: A Randomized Controlled Trial (2005) (162)
A combined genomewide linkage scan of 1,233 families for prostate cancer-susceptibility genes conducted by the international consortium for prostate cancer genetics. (2005) (161)
Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017. (2017) (160)
A randomized trial of perioperative hemodilution versus transfusion of preoperatively deposited autologous blood in elective surgery (1992) (157)
Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance program. (2010) (156)
Correlation of prostatic nuclear androgen receptor content with duration of response and survival following hormonal therapy in advanced prostatic cancer. (1982) (155)
Linkage and association studies of prostate cancer susceptibility: evidence for linkage at 8p22-23. (2001) (155)
Risk of cancer in relatives of prostate cancer probands. (1995) (154)
Adenocarcinoma of the prostate invading the seminal vesicle: prognostic stratification based on pathologic parameters. (2000) (153)
Prostate-specific antigen variability in men without prostate cancer: effect of sampling interval on prostate-specific antigen velocity. (1995) (150)
Hormonal regulation of testicular descent: experimental and clinical observations. (1977) (150)
Adenocarcinoma of the prostate invading the seminal vesicle: definition and relation of tumor volume, grade and margins of resection to prognosis. (1993) (149)
Patient-reported impotence and incontinence after nerve-sparing radical prostatectomy. (1998) (149)
An evaluation of the decreasing incidence of positive surgical margins in a large retropubic prostatectomy series. (2004) (148)
Management of stage D1 adenocarcinoma of the prostate: the Johns Hopkins experience 1974 to 1987. (1990) (147)
Evaluation of transrectal ultrasound in the early detection of prostate cancer. (1989) (145)
Radical prostatectomy for clinical stage T3a disease (2007) (144)
Radical prostatectomy for impalpable prostate cancer: the Johns Hopkins experience with tumors found on transurethral resection (stages T1A and T1B) and on needle biopsy (stage T1C). (1994) (143)
Anatomical studies of the neurovascular bundle and cavernosal nerves. (2005) (142)
Longitudinal evaluation of serum androgen levels in men with and without prostate cancer (1995) (140)
Association between two unlinked loci at 8q24 and prostate cancer risk among European Americans. (2007) (140)
The influence of hormonal therapy on survival of men with advanced prostatic cancer. (1982) (140)
Original Articles: Prostate Cancer: Pathological Features of Hereditary Prostate Cancer (1995) (136)
Radical retropubic prostatectomy. Improved anastomosis and urinary continence. (1990) (135)
Androgen- and estrogen-receptor content in spontaneous and experimentally induced canine prostatic hyperplasia. (1980) (134)
Quantitative GSTP1 methylation and the detection of prostate adenocarcinoma in sextant biopsies. (2003) (134)
The discovery of the cavernous nerves and development of nerve sparing radical retropubic prostatectomy. (2007) (133)
Variation in course of cavernous nerve with special reference to details of topographic relationships near prostatic apex: histologic study using male cadavers. (2005) (133)
What are the outcomes of radical prostatectomy for high-risk prostate cancer? (2009) (133)
Radical prostatectomy, preservation of sexual function, cancer control. The controversy. (1987) (132)
Associations between hOGG1 sequence variants and prostate cancer susceptibility. (2002) (132)
Complication rates and risk factors of 5802 transrectal ultrasound-guided sextant biopsies of the prostate within a population-based screening program. (2003) (131)
RNASEL Arg462Gln variant is implicated in up to 13% of prostate cancer cases. (2003) (130)
Prostate specific antigen progression in men with lymph node metastases following radical prostatectomy: results of long-term followup. (2004) (129)
Spontaneous benign prostatic hyperplasia in the beagle. Age-associated changes in serum hormone levels, and the morphology and secretory function of the canine prostate. (1983) (129)
Prostatic duct adenocarcinoma. Findings at radical prostatectomy (1991) (128)
The role of radical prostatectomy in the management of prostatic cancer (1987) (127)
Long-term cancer control of radical prostatectomy in men younger than 50 years of age: update 2003. (2003) (125)
The impact of anatomical radical retropubic prostatectomy on cancer control: the 30-year anniversary. (2012) (125)
Pituitary and gonadal hormones in patients with varicocele. (1975) (124)
Physiologic basis for hormonal theapy in carcinoma of the prostate. (1975) (124)
Intussusception of the reconstructed bladder neck leads to earlier continence after radical prostatectomy. (2002) (123)
A prospective study on the intake of animal products and risk of prostate cancer. (2002) (122)
Radical prostatectomy for the treatment of localized prostatic carcinoma. (1980) (122)
Estrogen receptors in the human prostate, seminal vesicle, epididymis, testis, and genital skin: a marker for estrogen-responsive tissues? (1980) (120)
Cancer control following anatomical radical prostatectomy: an interim report. (1991) (120)
The influence of reversible androgen deprivation on serum prostate-specific antigen levels in men with benign prostatic hyperplasia. (1989) (118)
A structured debate: immediate versus deferred androgen suppression in prostate cancer-evidence for deferred treatment. (2001) (117)
Decreased gene expression of steroid 5 alpha‐reductase 2 in human prostate cancer: Implications for finasteride therapy of prostate carcinoma (2003) (117)
Control of LH and FSH secretion in the male: Evidence that aromatization of androgens to estradiol is not required for inhibition of gonadotropin secretion. (1972) (117)
Characteristics of prostate cancer in families potentially linked to the hereditary prostate cancer 1 (HPC1) locus (1997) (116)
Local recurrence and survival following nerve-sparing radical cystoprostatectomy. (1990) (116)
American Society of Clinical Oncology recommendations for the initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer. (2005) (114)
Defining sexual outcomes after treatment for localized prostate carcinoma. (2003) (114)
Evaluation of linkage and association of HPC2/ELAC2 in patients with familial or sporadic prostate cancer. (2001) (114)
Inherited genetic variant predisposes to aggressive but not indolent prostate cancer (2010) (113)
Cavernous nerve grafts restore erectile function in denervated rats. (1991) (113)
Early age at diagnosis in families providing evidence of linkage to the hereditary prostate cancer locus (HPC1) on chromosome 1. (1997) (113)
Preservation of accessory pudendal arteries during radical retropubic prostatectomy: surgical technique and results. (2004) (112)
Treatment of benign prostatic hyperplasia. (1996) (112)
Sexual function and bother after radical prostatectomy or radiation for prostate cancer: multivariate quality-of-life analysis from CaPSURE. (2000) (111)
Prostate volume changes over time: results from the Baltimore Longitudinal Study of Aging. (2009) (111)
Estrogen receptors in human prostate: evidence for multiple binding sites. (1983) (111)
Radical Pelvic Surgery with Preservation of Sexual Function (1988) (110)
Genetic susceptibility of benign prostatic hyperplasia. (1994) (110)
Individual and cumulative effect of prostate cancer risk‐associated variants on clinicopathologic variables in 5,895 prostate cancer patients (2009) (108)
Prostate cancer, version 1.2014. (2013) (108)
Common sequence variants of the macrophage scavenger receptor 1 gene are associated with prostate cancer risk. (2003) (108)
Radical retropubic prostatectomy with reduced morbidity: an anatomic approach. (1988) (107)
A comparison of transurethral surgery with watchful waiting for moderate symptoms of benign prostatic hyperplasia. (1995) (107)
The effect of finasteride in men with benign prostatic hyperplasia. 1992. (2002) (107)
Stage D1 (T1-3, N1-3, M0) prostate cancer: a case-controlled comparison of conservative treatment versus radical prostatectomy. (1997) (106)
The use of percent free prostate specific antigen for staging clinically localized prostate cancer. (1998) (105)
A microassay for the measurement of androgen receptors in human prostatic tissue (1979) (104)
High anterior release of the levator fascia improves sexual function following open radical retropubic prostatectomy. (2008) (104)
A Polymorphism in the CDKN1B Gene Is Associated with Increased Risk of Hereditary Prostate Cancer (2004) (104)
Long-term 6-year experience with finasteride in patients with benign prostatic hyperplasia. (2003) (101)
RADICAL PROSTATECTOMY FOR LOCALIZED PROSTATE CANCER PROVIDES DURABLE CANCER CONTROL WITH EXCELLENT QUALITY OF LIFE: A STRUCTURED DEBATE (2000) (100)
The significance of positive surgical margin in areas of capsular incision in otherwise organ confined disease at radical prostatectomy. (2007) (100)
Prognostic significance of Gleason score discrepancies between needle biopsy and radical prostatectomy. (2008) (98)
Subcellular distribution of androgen receptors in human normal, benign hyperplastic, and malignant prostatic tissues: characterization of nuclear salt-resistant receptors. (1983) (98)
Familial persistent Müllerian duct syndrome. (1976) (98)
Pathological outcomes in men with low risk and very low risk prostate cancer: implications on the practice of active surveillance. (2013) (97)
Partial androgen insensitivity: the Reifenstein syndrome revisited. (1977) (97)
Prostate cancer recurrence in radical surgery patients receiving autologous or homologous blood (1992) (97)
Characteristics of prostate cancer in families potentially linked to the hereditary prostate cancer 1 (HPC1) locus. (1998) (96)
Prognostic factors in men with stage D1 prostate cancer: identification of patients less likely to have prolonged survival after radical prostatectomy. (1994) (96)
Dedifferentiation of prostate cancer grade with time in men followed expectantly for stage T1c disease. (2001) (95)
Characterization of the binding of a potent synthetic androgen, methyltrienolone, to human tissues. (1978) (95)
Survival of blacks and whites after a cancer diagnosis. (2002) (95)
Comparison of radical prostatectomy and iodine 125 interstitial radiotherapy for the treatment of clinically localized prostate cancer: a 7-year biochemical (PSA) progression analysis. (1998) (94)
Joint effect of HSD3B1 and HSD3B2 genes is associated with hereditary and sporadic prostate cancer susceptibility. (2002) (94)
Trefoil factor 3 overexpression in prostatic carcinoma: Prognostic importance using tissue microarrays (2004) (94)
The association of body mass index and prostate-specific antigen in a population-based study. (2005) (93)
Clinical practice. Localized prostate cancer. (2007) (93)
NCCN Prostate Cancer Practice Guidelines. The National Comprehensive Cancer Network. (1996) (93)
The management of rectal injury during radical retropubic prostatectomy. (1992) (93)
Androgenic sensitivity of the gubernaculum testis: evidence for hormonal/mechanical interactions in testicular descent. (1982) (93)
Disease progression following radical prostatectomy in men with Gleason score 7 tumor. (1998) (93)
Small high grade adenocarcinoma of the prostate in radical prostatectomy specimens performed for nonpalpable disease: pathogenetic and clinical implications. (1994) (92)
Mechanisms of recurrent varicocele after balloon occlusion or surgical ligation of the internal spermatic vein. (1983) (91)
Expectant management of prostate cancer with curative intent: an update of the Johns Hopkins experience (2007) (91)
Radical retropubic prostatectomy: the influence of accessory pudendal arteries on the recovery of sexual function. (1995) (91)
Campbell's urology (2013) (91)
Alpha-methylacyl-CoA racemase: a new molecular marker for prostate cancer. (2002) (90)
Changes in the metabolism of dihydrotestosterone in the hyperplastic human prostate. (1983) (90)
Combined genome-wide scan for prostate cancer susceptibility genes. (2004) (89)
Evidence for a Prostate Cancer Susceptibility Locus on the X Chromosome (1999) (88)
Polymorphic GGC repeats in the androgen receptor gene are associated with hereditary and sporadic prostate cancer risk (2002) (88)
Efficacy of first-generation Cavermap to verify location and function of cavernous nerves during radical prostatectomy: a multi-institutional evaluation by experienced surgeons. (2001) (88)
Early androgen deprivation for prostate cancer? (1999) (87)
Prediction of post-radical prostatectomy pathological outcome for stage T1c prostate cancer with percent free prostate specific antigen: a prospective multicenter clinical trial. (1999) (87)
Standard versus age-specific prostate specific antigen reference ranges among men with clinically localized prostate cancer: A pathological analysis. (1996) (87)
Biological aggressiveness of hereditary prostate cancer: long-term evaluation following radical prostatectomy. (1998) (86)
Linkage of prostate cancer susceptibility loci to chromosome 1 (2001) (86)
Re: “Obesity and hormone‐dependent tumors: cohort and co‐twin control studies based on the Swedish twin registry” (2003) (85)
Radical prostatectomy for high grade disease: a reevaluation 1994. (1994) (85)
Use of intraoperative video documentation to improve sexual function after radical retropubic prostatectomy. (2000) (84)
Impact of surgical delay on long-term cancer control for clinically localized prostate cancer. (2004) (84)
Importance of posterolateral needle biopsies in the detection of prostate cancer. (2001) (84)
LH-hCG receptors and testosterone content during differentiation of the testis in the rabbit embryo. (1975) (83)
The incidence of intersexuality in patients with hypospadias and cryptorchidism. (1976) (83)
A critical analysis of the interpretation of biochemical failure in surgically treated patients using the American Society for Therapeutic Radiation and Oncology criteria. (2002) (83)
Prediction of extraprostatic extension in the neurovascular bundle based on prostate needle biopsy pathology, serum prostate specific antigen and digital rectal examination. (2005) (83)
Nerve grafts are rarely necessary and are unlikely to improve sexual function in men undergoing anatomic radical prostatectomy. (2001) (83)
Pathological features of hereditary prostate cancer. (1995) (82)
Retroperitoneal lymphadenectomy for testicular tumors. (1971) (82)
Does capsular incision at radical retropubic prostatectomy affect disease-free survival in otherwise organ-confined prostate cancer? (2001) (82)
Germline mutations in ATM and BRCA1/2 distinguish risk for lethal and indolent prostate cancer and are associated with early age at death (2017) (82)
Probability of biochemical recurrence by analysis of pathologic stage, Gleason score, and margin status for localized prostate cancer. (2003) (81)
Genome‐wide scan for prostate cancer susceptibility genes in the Johns Hopkins hereditary prostate cancer families (2003) (81)
Impact of surgical margin status on prostate‐cancer‐specific mortality (2012) (81)
Cigarette smoking and prostate cancer recurrence after prostatectomy. (2011) (81)
Family history of prostate cancer and obesity in relation to high‐grade disease and extraprostatic extension in young men with prostate cancer (2003) (80)
Systematic detection and repair of subclinical inguinal hernias at radical retropubic prostatectomy. (2005) (80)
What the U.S. Preventive Services Task Force Missed in Its Prostate Cancer Screening Recommendation (2012) (80)
Weight Gain Is Associated with an Increased Risk of Prostate Cancer Recurrence after Prostatectomy in the PSA Era (2011) (79)
Nerve growth factor, nerve grafts and amniotic membrane grafts restore erectile function in rats. (1991) (79)
Natural history of pathologically organ-confined (pT2), Gleason score 6 or less, prostate cancer after radical prostatectomy. (2008) (79)
Positive proximal (bladder neck) margin at radical prostatectomy confers greater risk of biochemical progression. (2004) (78)
The Melbourne Consensus Statement on the early detection of prostate cancer (2014) (78)
A neural network predicts progression for men with gleason score 3+4 versus 4+3 tumors after radical prostatectomy. (2000) (77)
Incidence and mortality of testicular and prostatic cancers in relation to world dietary practices. (2002) (77)
The endocrinology of human chorionic gonadotropin-secreting testicular tumors: new methods in diagnosis. (1975) (76)
The prostatic specific antigen era is alive and well: prostatic specific antigen and biochemical progression following radical prostatectomy. (2005) (75)
Prostate cancer tumor volume: measurement with endorectal MR and MR spectroscopic imaging. (2002) (75)
The influence of finasteride on the volume of the peripheral and periurethral zones of the prostate in men with benign prostatic hyperplasia (1993) (75)
Human benign prostatic hyperplasia: etiological considerations. (1984) (74)
Cancer in US Air Force Veterans of the Vietnam War. (2005) (73)
The volume and anatomical location of residual tumor in radical prostatectomy specimens removed for stage A1 prostate cancer. (1988) (72)
Effect of reversible androgen deprivation on hemoglobin and serum immunoreactive erythropoietin in men (1991) (71)
The role of preoperative endorectal magnetic resonance imaging in the decision regarding whether to preserve or resect neurovascular bundles during radical retropubic prostatectomy. (2005) (71)
Contemporary identification of patients at high risk of early prostate cancer recurrence after radical retropubic prostatectomy. (2001) (71)
Thromboembolic complications following radical retropubic prostatectomy. Influence of external sequential pneumatic compression devices. (1993) (70)
NCCN Practice Guidelines for Prostate Cancer. (2000) (69)
Prostate Cancer Risk Associated Loci in African Americans (2009) (69)
Elevated pressure in the left renal vein in patients with varicocele: preliminary observations. (1980) (69)
Association of Prostate Cancer Risk Variants with Clinicopathologic Characteristics of the Disease (2008) (69)
Family history facilitates the early diagnosis of prostate carcinoma (1997) (69)
A contemporary analysis of outcomes of adenocarcinoma of the prostate with seminal vesicle invasion (pT3b) after radical prostatectomy. (2011) (69)
Predictors of cancer in repeat extended multisite prostate biopsy in men with previous negative extended multisite biopsy. (2003) (68)
Treatment with finasteride preserves usefulness of prostate-specific antigen in the detection of prostate cancer: results of a randomized, double-blind, placebo-controlled clinical trial. (1999) (68)
Surgery and the reduction of mortality from prostate cancer. (2002) (67)
Suppression of plasma androgens by spironolactone in castrated men with carcinoma of the prostate. (1975) (67)
Cyproterone acetate in the treatment of advanced carcinoma of the prostate. (1973) (67)
Occlusion of varicoceles wih detachable balloons. (1981) (67)
Biochemical failure after radical prostatectomy in men with pathologic organ‐confined disease: pT2a versus pT2b (2004) (64)
Prostate carcinoma: Radiation treatment of the primary and regional lymphatics (1974) (64)
Concordance rates for benign prostatic disease among twins suggest hereditary influence. (1994) (64)
Plasma androgen responce to hCG stimulation in prepubertal boys with hypospadias and cryptorchidism. (1976) (64)
Polymorphisms in the CYP1A1 gene are associated with prostate cancer risk (2003) (63)
The natural history of men treated with deferred androgen deprivation therapy in whom metastatic prostate cancer developed following radical prostatectomy. (2008) (63)
Stronger Association between Obesity and Biochemical Progression after Radical Prostatectomy among Men Treated in the Last 10 Years (2005) (63)
Clinical and endocrinologic characterization of a patients with the syndrome of incomplete testicular feminization. (1975) (63)
Frozen section detection of lymph node metastases in prostatic carcinoma: accuracy in grossly uninvolved pelvic lymphadenectomy specimens. (1986) (63)
Increased gene copy number of ERG on chromosome 21 but not TMPRSS2–ERG fusion predicts outcome in prostatic adenocarcinomas (2011) (62)
Erratum: An updated prostate cancer staging nomogram (partin tables) based on cases from 2006 to 2011 (BJU International 111 (22-29)) (2013) (62)
Testosterone and oestradiol suppression of LH and FSH in adult male rats: duration of castration, duration of treatment and combined treatment. (1973) (62)
Excision of the neurovascular bundle at radical prostatectomy in cases with perineural invasion on needle biopsy. (1999) (62)
Cumulative effect of five genetic variants on prostate cancer risk in multiple study populations (2008) (61)
Germ-line mutation of NKX3.1 cosegregates with hereditary prostate cancer and alters the homeodomain structure and function. (2006) (61)
Polymorphisms in the CYP1B1 gene are associated with increased risk of prostate cancer (2003) (60)
Elevated plasma testosterone and gonadotropin levels in infertile males with hyperthyroidism. (1976) (60)
No evidence for a role of BRCA1 or BRCA2 mutations in Ashkenazi Jewish families with hereditary prostate cancer (1999) (59)
Cause-specific actuarial survival analysis: a useful method for reporting survival data in men with clinically localized carcinoma of the prostate. (1989) (59)
Ability to Predict Metastasis Based On Pathology Findings and Alterations in Nuclear Structure Of Normal-Appearing and Cancer Peripheral Zone Epithelium in the Prostate (2004) (59)
Identification of an inherited form of Peyronie's disease with autosomal dominant inheritance and association with Dupuytren's contracture and histocompatibility B7 cross-reacting antigens. (1984) (59)
The inability of adrenal androgens to stimulate the adult human prostate: an autopsy evaluation of men with hypogonadotropic hypogonadism and panhypopituitarism. (1986) (59)
Prostate cancer kills: strategy to reduce deaths. (1994) (59)
Influence of biopsy perineural invasion on long-term biochemical disease-free survival after radical prostatectomy. (2002) (58)
Long-term survival after radical prostatectomy for men with high Gleason sum in pathologic specimen. (2010) (58)
A novel prostate cancer susceptibility locus at 19q13. (2009) (58)
Is it possible to compare PSA recurrence-free survival after surgery and radiotherapy using revised ASTRO criterion--"nadir + 2"? (2008) (57)
Deoxyribonucleic acid ploidy analysis as a predictor of recurrence following radical prostatectomy for stage T2 disease. (1995) (57)
Needle biopsy associated tumor tracking of adenocarcinoma of the prostate. (1991) (57)
Association of statin use with pathological tumor characteristics and prostate cancer recurrence after surgery. (2011) (57)
Sequence Variants of α-Methylacyl-CoA Racemase Are Associated with Prostate Cancer Risk (2002) (56)
Linkage and association of CYP17 gene in hereditary and sporadic prostate cancer (2001) (55)
Association between sequence variants at 17q12 and 17q24.3 and prostate cancer risk in European and African Americans (2008) (55)
Screening for prostate cancer: an update of the evidence for the U.S. Preventive Services Task Force. (2003) (54)
Simultaneous preperitoneal hernia repair during radical pelvic surgery. (1987) (53)
Radical retropubic prostatectomy. How often do experienced surgeons have positive surgical margins when there is extraprostatic extension in the region of the neurovascular bundle? (2005) (53)
Percentage of free PSA in black versus white men for detection and staging of prostate cancer: a prospective multicenter clinical trial. (2000) (53)
Association of cigarette smoking with extraprostatic prostate cancer in young men. (2003) (53)
Invasion of the neurovascular bundle by prostate cancer: evaluation with MR imaging. (1991) (53)
Pathological and oncologic outcomes for men with positive lymph nodes at radical prostatectomy: The Johns Hopkins Hospital 30‐year experience (2013) (52)
Re: The prostate cancer conundrum revisited: treatment changes and prostate cancer mortality declines. (2012) (52)
Cystic lesions of the prostate gland. A sonographic‐‐pathologic correlation. (1990) (52)
Ability of the 1992 and 1997 American Joint Committee on Cancer staging systems for prostate cancer to predict progression-free survival after radical prostatectomy for stage T2 disease. (2000) (52)
Digital rectal examination and imaging studies are unnecessary in men with undetectable prostate specific antigen following radical prostatectomy. (1999) (52)
Simultaneous measurement of progesterone and androgen receptors in human prostate: a microassay. (1982) (52)
Risks and benefits of soy phytoestrogens in cardiovascular diseases, cancer, climacteric symptoms and osteoporosis. (2002) (51)
Genome‐wide screen for prostate cancer susceptibility genes in men with clinically significant disease (2005) (51)
Evidence for a prostate cancer linkage to chromosome 20 in 159 hereditary prostate cancer families (2001) (51)
Peyronie's disease: a newly recognized autosomal-dominant trait. (1982) (50)
Postoperative bleeding following radical retropubic prostatectomy. (1994) (50)
The role of radical prostatectomy in the treatment of prostate cancer (1992) (50)
Long-term survival after hormonal therapy for stage D prostatic cancer. (1979) (50)
Pathologic findings in clinical stage A2 prostate cancer. Relation of tumor volume, grade, and location to pathologic stage (1990) (50)
Blood transfusion and anesthetic practices in radical retropubic prostatectomy. (1985) (49)
The ontogeny of the androgen receptor in human foreskin. (1981) (49)
Efficacy of continuous local anesthetic infusion for postoperative pain after radical retropubic prostatectomy. (2005) (49)
The definition and preoperative prediction of clinically insignificant prostate cancer. (1996) (48)
Using Prostate-specific Antigen To Diagnose Prostate Cancer: Sailing in Uncharted Waters (1993) (48)
Why make an early diagnosis of prostate cancer. (1992) (48)
Anatomic extent of pelvic lymph node dissection: impact on long-term cancer-specific outcomes in men with positive lymph nodes at time of radical prostatectomy. (2013) (47)
Nonpalpable prostate cancer: detection with MR imaging. (1991) (47)
Familial study of prostate cancer in Jamaica. (1998) (46)
Methods for the determination of androgen receptor content in human prostatic tissue. (1981) (46)
Dysgenetic male pseudohermaphroditism. (1978) (46)
20-year outcomes following conservative management of clinically localized prostate cancer. (2005) (46)
The relationship between the extent of extraprostatic extension and survival following radical prostatectomy. (2015) (45)
The use of multiple variables to predict response to endocrine therapy in carcinoma of the prostate: a preliminary report. (1984) (45)
Obesity and long-term survival after radical prostatectomy. (2014) (45)
Ileocolic neobladder post-cystectomy: continence and potency. (1991) (45)
Clinical and biological characteristics of familial benign prostatic hyperplasia. (1997) (45)
Androgen receptor content of normal and hyperplastic human prostate. (1982) (45)
Surgery-Related Factors and Local Recurrence of Wilms Tumor in National Wilms Tumor Study 4 (1999) (45)
Clinical and endocrinological evaluation of patients with congenital microphallus. (1978) (44)
Prevalence of Prostate Cancer Among Men With a Prostate-Specific Antigen Level ≤4.0 ng per Milliliter (2004) (44)
Preoperative characteristics of high‐Gleason disease predictive of favourable pathological and clinical outcomes at radical prostatectomy (2012) (44)
Molecular and immunohistochemical staging of men with seminal vesicle invasion and negative pelvic lymph nodes at radical prostatectomy (2000) (44)
In situ management of renal tumors: renal cell carcinoma and transitional cell carcinoma. (1984) (43)
Immediate versus deferred hormonal treatment for patients with prostate cancer who are not suitable for curative local treatment: results of the randomized trial SAKK 08/88. (2005) (43)
The measurement of androgen receptors in human prostatic tissue utilizing sucrose density centrifugation and a protamine precipitation assay. (1977) (43)
Tumor volume versus percentage of specimen involved by tumor correlated with progression in stage A prostatic cancer. (1988) (43)
Effect of treatment with 5‐α reductase inhibitors on progression in monitored men with favourable‐risk prostate cancer (2012) (43)
Can we stop prostate specific antigen testing 10 years after radical prostatectomy? (2011) (43)
The significance of prior benign needle biopsies in men subsequently diagnosed with prostate cancer. (1999) (43)
Predicting Cancer Following a Diagnosis of High-Grade Prostatic Intraepithelial Neoplasia on Needle Biopsy: Data on Men With More Than One Follow-Up Biopsy (2002) (43)
Associations between hOGG1 sequence variants and prostate cancer susceptibility. (2002) (42)
Heterogeneity of genetic alterations in prostate cancer: evidence of the complex nature of the disease. (2002) (42)
Effect of methylprednisolone on return of sexual function after nerve-sparing radical retropubic prostatectomy. (2004) (42)
Correlation of prostate cancer nuclear deoxyribonucleic acid, size, shape and Gleason grade with pathological stage at radical prostatectomy. (1992) (42)
Evaluation of a monoclonal immunoradiometric assay for prostate-specific antigen. (1987) (42)
Prostate cancer localization with endorectal MR imaging and MR spectroscopic imaging: effect of clinical data on reader accuracy. (2005) (42)
Chromosome 8q24 risk variants in hereditary and non‐hereditary prostate cancer patients (2008) (42)
Androgen-deprivation therapy in prostate cancer and cardiovascular risk: A science advisory from the American heart association, American cancer society, and American urological association: Endorsed by the American society for radiation oncology (2010) (42)
Patient-reported urinary continence and sexual function after anatomic radical prostatectomy. (2000) (41)
Familial risk factors for prostate cancer. (1991) (41)
Quantitative alterations in nuclear structure predict prostate carcinoma distant metastasis and death in men with biochemical recurrence after radical prostatectomy (2003) (41)
Does prophylactic breast irradiation prevent antiandrogen-induced gynecomastia? Evaluation of 253 patients in the randomized Scandinavian trial SPCG-7/SFUO-3. (2003) (40)
Re: Statin Medication Use and the Risk of Biochemical Recurrence After Radical Prostatectomy: Results From the Shared Equal Access Regional Cancer Hospital (SEARCH) Database (2011) (40)
Sonography in the diagnosis of retroperitoneal fibrosis. (1977) (40)
Androgen, estrogen and progesterone receptors of the R3327H Copenhagen rat prostatic tumor. (1979) (39)
Long-term results of radical prostatectomy in clinically localized prostate cancer: experience at the Johns Hopkins Hospital. (1988) (39)
Pathological stage is higher in older men with clinical stage B1 adenocarcinoma of the prostate. (1989) (39)
Relationship between primary Gleason pattern on needle biopsy and clinicopathologic outcomes among men with Gleason score 7 adenocarcinoma of the prostate. (2006) (39)
Computerized Tomography and Lymphangiography in Staging Testis Tumors (1981) (38)
Balloon occlusion of the internal spermatic vein for the treatment of varicoceles. (1981) (38)
Racial Differences in Initial Treatment for Clinically Localized Prostate Cancer. Results From the Prostate Cancer Outcomes Study (2004) (38)
Capsular transgression of prostatic carcinoma: evaluation with transrectal US with pathologic correlation. (1991) (38)
Concordance Rates and Modifiable Risk Factors for Lower Urinary Tract Symptoms in Twins (2006) (37)
Effect of finasteride on prostate-specific antigen density. (1994) (37)
Mechanism of androgenic action: effect of specific intracellular inhibitors. (1971) (37)
Compelling evidence for a prostate cancer gene at 22q12.3 by the International Consortium for Prostate Cancer Genetics. (2007) (37)
Prostate-specific antigen doubling time in the identification of patients at risk for progression after treatment and biochemical recurrence for prostate cancer. (2003) (36)
Black race does not independently predict adverse outcome following radical retropubic prostatectomy at a tertiary referral center. (2006) (36)
Prospective, multicenter, randomized phase II trial of the herbal supplement, PC-SPES, and diethylstilbestrol in patients with androgen-independent prostate cancer. (2005) (36)
Incontinence after radical prostatectomy (1999) (36)
Progression after radical prostatectomy for men in their thirties compared to older men (2008) (36)
Biphasic effect of testosterone on spermatogenesis in the rat. (1973) (36)
Serum acid phosphatase level and biochemical recurrence following radical prostatectomy for men with clinically localized prostate cancer. (2001) (35)
The relationship of prostate specific antigen levels and residual tumor volume in stage A prostate cancer. (1990) (35)
Familial aggregation of bothersome benign prostatic hyperplasia symptoms. (2003) (34)
Improved hemostasis during simple retropubic prostatectomy. (1990) (34)
Elevation of serum gonadotropins establishes the diagnosis of anorchism in prepubertal boys with bilateral cryptorchidism. (1986) (34)
Extrarenal manifestations of renal cell carcinoma. (1977) (34)
Follow-up prostate cancer treatments after radical prostatectomy: a population-based study. (1996) (33)
Dietary supplement use in the Prostate Cancer Prevention trial: implications for prevention trials. (2003) (33)
Endocrine evaluation of adults with mild hypospadias. (1990) (33)
Screening for prostate cancer. American College of Physicians. (1997) (33)
A novel founder mutation in the RNASEL gene, 471delAAAG, is associated with prostate cancer in Ashkenazi Jews. (2003) (32)
Salvage or adjuvant radiation therapy: counseling patients on the benefits. (2010) (32)
Genome-wide association of familial prostate cancer cases identifies evidence for a rare segregating haplotype at 8q24.21 (2016) (32)
Hereditary prostate cancer in African American families: linkage analysis using markers that map to five candidate susceptibility loci (2004) (31)
Incidental non-Hodgkin's lymphoma in patients with localized prostate cancer. (1999) (31)
Nerve sparing radical prostatectomy for early stage prostate cancer. (1988) (31)
Critical appraisal of management of rectal injury during radical prostatectomy. (2010) (31)
Radical prostatectomy: a procedure in evolution. (1994) (31)
The use of the preperitoneal approach for the simultaneous repair of inguinal hernia during surgery on the bladder and prostate (1989) (31)
Interaction effect of PTEN and CDKN1B chromosomal regions on prostate cancer linkage (2003) (31)
The value of serum enzymatic acid phosphatase in the staging of localized prostate cancer. (1992) (31)
(In)-efficacy of salvage radiotherapy for rising PSA or clinically isolated local recurrence after radical prostatectomy. (2003) (31)
Can aggressive prostatic carcinomas be identified and can their natural history be altered by treatment? (1995) (30)
Increased Risk of Rectal Cancer After Prostate Radiation: A Population-Based Study (2005) (30)
Baicalin is a Major Component of PC-SPES Which Inhibits the Proliferation of Human Cancer Cells Via Apoptosis and Cell Cycle Arrest (2002) (30)
Characterization of the primate luteinizing hormone receptor in testis homogenates and Leydig cells. (1979) (30)
Today men with prostate cancer have larger prostates. (2000) (30)
Idiopathic retroperitoneal fibrosis. (1979) (30)
Re: The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. (1994) (30)
Radiation Therapy in the Definitive Management of Oligometastatic Prostate Cancer: The Johns Hopkins Experience (2019) (30)
Evaluation of SRD5A2 sequence variants in susceptibility to hereditary and sporadic prostate cancer (2003) (29)
Stage B adenocarcinoma of the prostate: transrectal US and pathologic correlation of nonmalignant hypoechoic peripheral zone lesions. (1991) (29)
Single nucleotide polymorphisms and the likelihood of prostate cancer at a given prostate specific antigen level. (2009) (29)
Serum levels of phytanic acid are associated with prostate cancer risk. (2005) (29)
Pathological outcomes and biochemical progression in men with T1c prostate cancer undergoing radical prostatectomy with prostate specific antigen 2.6 to 4.0 vs 4.1 to 6.0 ng/ml. (2006) (29)
Androgen receptors in human prostatic tissues: a review. (1977) (29)
Prospective comparison of radical retropubic prostatectomy and robot-assisted anatomic prostatectomy: the Vattikuti Urology Institute experience. (2003) (29)
Radical prostatectomy in older men: survival outcomes in septuagenarians and octogenarians (2010) (29)
Sequence variants of alpha-methylacyl-CoA racemase are associated with prostate cancer risk. (2002) (29)
Vitamin E supplements and risk of prostate cancer in U.S. men. (2005) (29)
Long-term results of radiation therapy for prostate cancer recurrence following radical prostatectomy: Reply by authors (1998) (28)
Rare Germline Pathogenic Mutations of DNA Repair Genes Are Most Strongly Associated with Grade Group 5 Prostate Cancer. (2020) (28)
Docetaxel Plus Prednisone or Mitoxantrone Plus Prednisone for Advanced Prostate Cancer (2005) (28)
Germline translocation t(5;20)(p15;q11) and familial transitional cell carcinoma. (1996) (28)
Long-term autopsy findings following radical prostatectomy. (1987) (28)
Isolated local recurrence is rare after radical prostatectomy in men with Gleason 7 prostate cancer and positive surgical margins: therapeutic implications. (2001) (28)
Role of prostate-specific antigen velocity in prediction of final pathologic stage in men with localized prostate cancer. (1997) (27)
Testicular descent. (1977) (27)
Anterior-predominant prostatic tumors: Zone of origin and pathologic outcomes at radical prostatectomy (2010) (27)
Editorial: The Status of Radical Prostatectomy in the United States in 1993: Where do we go from here? (1994) (27)
Computerized Tomography in the Diagnosis of Retroperitoneal Fibrosis (1981) (27)
Substratification of stage T1C prostate cancer based on the probability of biochemical recurrence. (2002) (27)
Association analysis of 9,560 prostate cancer cases from the International Consortium of Prostate Cancer Genetics confirms the role of reported prostate cancer associated SNPs for familial disease (2014) (27)
Mutational analysis of PINX1 in hereditary prostate cancer (2004) (26)
A Germline Variant at 8q24 Contributes to Familial Clustering of Prostate Cancer in Men of African Ancestry. (2020) (26)
The significance of a positive bladder neck margin after radical prostatectomy: the American Joint Committee on Cancer Pathological Stage T4 designation is not warranted. (2010) (26)
Prevalence of the HOXB13 G84E prostate cancer risk allele in men treated with radical prostatectomy (2014) (26)
Intravenous zoledronic acid in postmenopausal women with low bone mineral density. (2002) (26)
Genome‐wide linkage analysis of 1,233 prostate cancer pedigrees from the International Consortium for prostate cancer Genetics using novel sumLINK and sumLOD analyses (2010) (26)
Characterization and measurement of androgen receptors in human prostatic tissue. (1979) (26)
A prospective study of physical activity and risk of prostate cancer in US physicians. (2002) (25)
High-Intensity Focused Ultrasound (HIFU) Followed After One to Two Weeks by Radical Retropubic Prostatectomy: Results of a Prospective Study (1999) (25)
Influence of prostate volume in the detection of prostate cancer. (2003) (25)
Adjuvant radiotherapy after radical prostatectomy: is it indicated? (1987) (25)
Utility of Risk Models in Decision Making After Radical Prostatectomy: Lessons from a Natural History Cohort of Intermediate- and High-Risk Men. (2016) (25)
Fever and prostatic mass in a young man. (1978) (25)
Stage A adenocarcinoma of the prostate: transrectal US and sonographic-pathologic correlation. (1991) (25)
Germline ATBF1 mutations and prostate cancer risk (2006) (24)
Lymphadenectomy combined with preoperative and postoperative cobalt 60 teletherapy in the management of embryonal carcinoma and teratocarcinoma of the testis. (1974) (24)
Identification of a prostate cancer susceptibility locus on chromosome 7q11–21 in Jewish families (2004) (24)
The Prostate: A Guide for Men and the Women Who Love Them (1995) (24)
A genetic variant near GATA3 implicated in inherited susceptibility and etiology of benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS) (2017) (24)
Screening for prostate cancer: recommendation and rationale. (2003) (24)
Bright echogenic foci in early prostatic carcinoma: sonographic and pathologic correlation. (1990) (24)
Radical surgery for prostatic cancer. (1980) (24)
Histopathologic characterization of hereditary benign prostatic hyperplasia. (1996) (24)
The echogenic focus in prostatic sonograms, with xeroradiographic and histopathologic correlation. (1986) (24)
The association of treatment-related symptoms with quality-of-life outcomes for localized prostate carcinoma patients. (2002) (23)
Balloon cuffing and management of the entrapped Foley catheter. (2003) (23)
Carcinoma of the prostate: value of transrectal sonography in detecting extension into the neurovascular bundle. (1990) (23)
Evaluation of DLC1 as a prostate cancer susceptibility gene: mutation screen and association study. (2003) (23)
Stereotactic ablative radiation therapy for oligometastatic prostate cancer delays time-to-next systemic treatment (2018) (23)
Validation of prostate cancer risk-related loci identified from genome-wide association studies using family-based association analysis: evidence from the International Consortium for Prostate Cancer Genetics (ICPCG) (2012) (23)
Suppression of tumorigenicity of human prostate carcinoma cells by replacing a mutated RB gene: Editorial comment (1990) (23)
The Swedish prostate cancer paradox. (1997) (22)
Sequence variants in the human 25‐hydroxyvitamin D3 1‐α‐hydroxylase (CYP27B1) gene are not associated with prostate cancer risk (2002) (22)
Does perineural invasion on prostate biopsy predict adverse prostatectomy outcomes? (2010) (22)
Intensive intravesical chemotherapy in the treatment of flat carcinoma in situ: is it safe? (1985) (22)
Predictive factors of urinary retention following prostate brachytherapy. (2003) (22)
Campbell Walsh Wein Urology (2021) (21)
Observed effect of age and body mass index on total and complexed PSA: analysis from a National Screening Program. (2005) (21)
Preservation of sexual function in men during radical pelvic surgery. (1990) (21)
Testicular descent. Normal and abnormal. (1978) (21)
Radical prostatectomy in men less than 50 years old. (1995) (21)
Radical Retropubic and Perineal Prostatectomy (2012) (21)
Treatment of early stage prostate cancer: radical prostatectomy. (1994) (21)
Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance program (2010) (20)
Nerve-Sparing Laparoscopic Radical Prostatectomy: Replicating the Open Surgical Technique (2005) (20)
Inhibition of extratesticular stimuli to prostatic growth in the castrate rat by antiandrogens. (1970) (20)
Impact of radical prostatectomy and TURP on the hypothalamic-pituitary-gonadal hormone axis. (2003) (20)
Early Feeding Compared With Nasogastric Decompression After Major Oncologic Gynecologic Surgery: A Randomized Study (1999) (19)
Germline sequence variants of the LZTS1 gene are associated with prostate cancer risk. (2002) (19)
Re: Prostate cancer in the elderly: frequency of advanced disease at presentation and disease-specific mortality. (2012) (19)
Race, Socioeconomic Status and Stage at Diagnosis for Five Common Malignancies (2004) (19)
Importance of tumor location in patients with high preoperative prostate specific antigen levels (greater than 20 ng/ml) treated with radical prostatectomy. (2007) (18)
This month in investigative urology. The role of estrogen/androgen synergism in the pathogenesis of benign prostatic hyperplasia (1988) (18)
The application of flow cytometry to the assessment of tumor cell heterogeneity and the grading of human prostatic cancer: preliminary results. (1986) (18)
The Gleason Grading System: A Complete Guide for Pathologists and Clinicians (2013) (18)
Anatomic approach for placement of surgical drains after radical retropubic prostatectomy: long-term effects on postoperative pain. (1996) (18)
P504S: A New Molecular Marker for the Detection of Prostate Carcinoma (2002) (17)
PSA Doubling Time and Absolute PSA Predict Metastasis-free Survival in Men With Biochemically Recurrent Prostate Cancer After Radical Prostatectomy. (2019) (17)
Impotence following radical prostatectomy: insight into etiology and prevention. 1982. (2002) (17)
The natural history of metastatic progression in men with PSA-recurrent prostate cancer after radical prostatectomy: 25-year follow-up. (2009) (16)
Prostate specific antigen at the initial diagnosis of metastasis to bone in patients after radical prostatectomy. (2010) (16)
Choriocarcinoma of the testis. (1974) (16)
Cyproterone: effect on serum gonadotropins in the male. (1972) (16)
Prostate cancer diagnosed after initial biopsy with atypical small acinar proliferation suspicious for malignancy is similar to cancer found on initial biopsy. (2003) (16)
Androgen and Estrogen Receptors in the Canine Prostate (1980) (16)
Analysis of the prostatic central zone in patients with unilateral absence of wolffian duct structures: further evidence of the mesodermal origin of the prostatic central zone. (1998) (15)
Computerized tomography in the diagnosis of retroperitoneal fibrosis. (1982) (15)
Urethrectomy with preservation of potency. (1990) (15)
2008 Whitmore Lecture: Radical prostatectomy--where we were and where we are going. (2009) (15)
Do Ultrasensitive Prostate Specific Antigen Measurements Have a Role in Predicting Long-Term Biochemical Recurrence-Free Survival in Men after Radical Prostatectomy? (2016) (15)
Risks of testosterone replacement. (2004) (15)
Two-locus genome-wide linkage scan for prostate cancer susceptibility genes with an interaction effect (2006) (15)
Feedback control of FSH in the male: role of oestrogen. (1973) (15)
Dr. Patrick Walsh's Guide to Surviving Prostate Cancer (2001) (15)
Radical prostatectomy as treatment for prostate-specific antigen-detected stage T1c prostate cancer (2005) (15)
Treatment of Non-Metastatic Rhabdomyosarcomas in Childhood and Adolescence. Results of the Second Study of the International Society of Paediatric Oncology: MMT84 (1999) (15)
Intermittent androgen deprivation for clinically localized prostate cancer: initial experience. (1998) (15)
Oral vs Intravenous Ciprofloxacin in the Initial Empirical Management of Severe Pyelonephritis or Complicated Urinary Tract Infections A Prospective Randomized Clinical Trial (1999) (15)
Radical retropubic prostatectomy and robotic-assisted laparoscopic prostatectomy: Likelihood of positive surgical margin(s) (2010) (14)
Implications of the prostate cancer prevention trial: a decision analysis model of survival outcomes. (2005) (14)
The case for open radical prostatectomy. (2010) (14)
Chromosomes 4 and 8 implicated in a genome wide SNP linkage scan of 762 prostate cancer families collected by the ICPCG (2012) (14)
Prostate‐specific antigen concentration in young men: new estimates and review of the literature (2012) (14)
A Large Cohort Study of Aspirin and Other Nonsteroidal Anti-Inflammatory Drugs and Prostate Cancer Incidence (2006) (14)
Prostatic intraepithelial neoplasia: Significance and correlation with prostate-specific antigen and transrectal ultrasound: Editorial comment (1990) (13)
The impact of preoperative erectile dysfunction on survival after radical prostatectomy (2010) (13)
The status of radical prostatectomy in the United States in 1993: where do we go from here? (1994) (13)
Occlusion of varicoceles with detachable balloons (1982) (13)
Nadir Prostate-Specific Antigen as a Predictor of Progression to Androgen-Independent Prostate Cancer (2002) (13)
CT Configuration of the Enlarged Adrenal Gland (1982) (13)
Infectious mononucleosis, other infections and prostate‐specific antigen concentration as a marker of prostate involvement during infection (2016) (12)
Does prostate growth confound prostate specific antigen velocity? Data from the Baltimore longitudinal study of aging. (2008) (12)
Re: Fatigue in Prostate Cancer Survivors Treated With Definitive Radiotherapy and LHRH Analogs (2011) (12)
The endocrinology of testicular tumors. (1977) (12)
Magnetic Resonance Imaging Prior to First Prostate Biopsy-Are we there yet? (2018) (12)
A Rare Germline HOXB13 Variant Contributes to Risk of Prostate Cancer in Men of African Ancestry (2022) (12)
POTENCY AND CONTINENCE FOLLOWING ANATOMIC RADICAL PROSTATECTOMY: PATIENT VERSUS PHYSICIAN REPORTED OUTCOMES (1999) (12)
A new cause of male infertility. (1979) (12)
Statins and Prostate Cancer Risk: A Case-Control Study (2006) (11)
Pathological analysis of the prostatic anterior fat pad at radical prostatectomy: insights from a prospective series (2017) (11)
Amyloidosis of the seminal vesicle and hematospermia. (2004) (11)
Natural History of Early, Localized Prostate Cancer (2004) (11)
Trends in immediate perioperative morbidity and delay in discharge after open and minimally invasive radical prostatectomy (RP): a 20‐year institutional experience (2013) (11)
Therapeutic efficacy of salvage cystectomy. Do results reflect natural history of bladder cancer? (1983) (11)
HOXB13 is a susceptibility gene for prostate cancer: results from the International Consortium for Prostate Cancer Genetics (ICPCG) (2012) (11)
Prostate-specific antigen after anatomic radical retropubic prostatectomy : Patterns of recurrence and cancer control : Prostate-specific antigen: the best prostatic tumor marker (1997) (11)
Modern prostate brachytherapy: prostate specific antigen results in 219 patients with up to 12 years of observed follow-up. (2001) (11)
Steroid receptor and biochemical profiles in prostatic cancer: correlation with response to hormonal treatment. (1987) (11)
Cervical cancer complicated by a pelvic kidney. (1980) (11)
Docetaxel and Estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer (2005) (11)
1162: Neuromodulation to Preserve Erectile Function After Radical Prostatectomy: Results from the GPI1485 Neuroimmunophilin Ligand Clinical Trial (2007) (10)
Associations between hOGG 1 Sequence Variants and Prostate Cancer Susceptibility 1 (2002) (10)
Re: Anatomical radical retropubic prostatectomy: detailed description of the surgical technique. (2004) (10)
Technique and outcomes of bladder neck intussusception during robot-assisted laparoscopic prostatectomy: A parallel comparative trial. (2016) (10)
Feedback regulation of gonadotropin secretion in men. (1973) (10)
Re: Infectious complications and hospital admissions after prostate biopsy in a European randomized trial. (2012) (10)
Transmission/disequilibrium tests of androgen receptor and glutathione S‐transferase pi variants in prostate cancer families (2002) (10)
Mass screening for prostate cancer: a comparative study in Natori, Japan and Changchun, China. (2003) (10)
Expectant Management of Prostate Cancer with Curative Intent (2001) (9)
Activity of müllerian-inhibiting substance in postnatal testes. (1973) (9)
Perfecting nerve-sparing radical prostatectomy: sailing in uncharted waters. (2008) (9)
Delayed intraoperative hydration limits blood loss during radical retropubic prostatectomy. (2005) (9)
Multiple cores of Gleason score 6 correlate with favourable findings at radical prostatectomy (2013) (9)
Nerve Sparing Radical Prostatectomy for Early Stage Prostate Cancer (1989) (9)
Endogenous and exogenous testosterone and the risk of prostate cancer and increased prostate specific antigen ( PSA ) : a meta-analysis (9)
The role of external beam radiotherapy with I-125/Pd-103 brachytherapy for prostate carcinoma. (2001) (9)
Preservation of sexual function in the surgical treatment of prostatic cancer--an anatomic surgical approach. (1988) (9)
Fine needle aspiration of the prostate--why has it taken so long to accept? (1986) (9)
The phenotypic expression of selective disorders of male sexual differentiation. (1978) (9)
Geographic patterns of prostate cancer mortality and variations in access to medical care in the United States. (2005) (8)
Editorial Comment: Minimally Invasive Treatment of Prostate Cancer (2001) (8)
Radical prostatectomy in locally confined prostatic carcinoma. (1990) (8)
Unilateral nerve-sparing radical prostatectomy and hemicystectomy in management of prostate sarcoma. (1993) (8)
The Search for the Missing Heritability of Prostate Cancer. (2017) (8)
Urological oncology: prostate cancer. (2010) (8)
The differential diagnosis of ambiguous genitalia in the newborn. (1978) (7)
Measurement of androgen receptors in human prostatic tissue: methodological considerations. (1976) (7)
Unscreened older men diagnosed with prostate cancer are at increased risk of aggressive disease (2017) (7)
Does benign prostatic hyperplasia treatment with alpha-blockers affect prostate cancer risk? (2013) (7)
Three considerations before advising 5-alpha-reductase inhibitors for chemoprevention. (2009) (7)
Fine‐needle core and aspiration biopsy. A new method for diagnosis of prostatic carcinoma (1990) (7)
High level of androgen receptor is associated with aggressive clinicopathologic features and decreased biochemical recurrence-free survival in prostate. Cancer patients treated with radical prostatectomy. (2005) (7)
Analysis of Xq27-28 linkage in the international consortium for prostate cancer genetics (ICPCG) families (2012) (7)
Ureterovaginoplasty for vaginal atresia (unique technique in treatment): a case report with description of associated arterial anomalies and retroiliac artery ureters. (1973) (7)
Germline mutations in PPFIBP2 are associated with lethal prostate cancer (2018) (7)
Re: Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working Group 2: T2 Substaging and Prostate Cancer Volume (2011) (7)
Original Articles: Prostate Cancer (1995) (7)
Re: High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized cancer. (2001) (7)
Re: Radical prostatectomy: the value of preoperative, individually labeled apical biopsies. (2001) (7)
Benign prostatic hyperplasia: etiological considerations. (1976) (7)
Re: "Obesity and hormone-dependent tumors: cohort and co-twin control studies based on the Swedish twin registry". (2006) (7)
Association of prostate cancer polygenic risk score with number and laterality of tumor cores in active surveillance patients (2021) (7)
UROLOGICAL SURVEY: ABSTRACTSUrologic Oncology: Prostate Cancer (2002) (7)
Skeletal muscle involvement by limited Gleason score 6 adenocarcinoma of the prostate on needle biopsy is not associated with adverse findings at radical prostatectomy. (2010) (7)
Predicting the long-term risk of prostate cancer-specific mortality after radical prostatectomy. (2009) (6)
Phase I Trial of 177Lutetium-Labeled J591, a Monoclonal Antibody to Prostate-Specific Membrane Antigen, in Patients With Androgen-Independent Prostate Cancer (2005) (6)
Prostate Specific Antigen Testing after Radical Prostatectomy—Can We Stop at 20 Years? (2017) (6)
Prostate-specific antigen and all-cause mortality: results from the Baltimore Longitudinal Study On Aging. (2004) (6)
Aortography in experimental renal failure. Evaluation of contrast media toxicity. (1970) (6)
Forgotten kidney: asynchronous bilateral ureteropelvic junction obstruction. (1978) (6)
1451: Prostate Specific Antigen Doubling Time after Radical Prostatectomy as a Predictor of Cause Specific Survival (2004) (6)
Randomized study of prostatic cancer. (1981) (6)
Rectal Complications After Modern Radiation for Prostate Cancer: A Colorectal Surgical Challenge (2005) (6)
Disease-specific survival following routine prostate cancer screening by digital rectal examination. (1993) (6)
Re: Dutasteride in localised prostate cancer management: the REDEEM randomised, double-blind, placebo-controlled trial. (2012) (6)
The role of estrogen/androgen synergism in the pathogenesis of benign prostatic hyperplasia. (1988) (6)
A prototype device for nonimmersion shock wave lithotripsy using ultrasonography for calculus localization. (1988) (6)
Re: Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. (2012) (6)
Laparoscopic radical prostatectomy: initial 70 cases at a U.S. university medical center. (2003) (6)
Renovascular hypertension: comparison of medical and surgical therapy. (1979) (6)
Lack of effect of a low-fat, high-fruit, -vegetable, and -fiber diet on serum prostate-specific antigen of men without prostate cancer: results from a randomized trial. (2003) (6)
The HOXB13 variant X285K is associated with clinical significance and early age at diagnosis in African American prostate cancer patients (2021) (6)
Failure definition-dependent differences in outcome following radiation for localized prostate cancer: can one size fit all? (2005) (6)
Clinical evaluation of human chorionic gonadotropin levels in men with testicular tumors. (1974) (5)
RE: IMMEDIATE VERSUS DEFERRED TREATMENT FOR ADVANCED PROSTATE CANCER: INITIAL RESULTS OF THE MEDICAL RESEARCH COUNCIL TRIAL (EDITORIAL COMMENT) (1998) (5)
Re: Prednisone Plus Cabazitaxel or Mitoxantrone for Metastatic Castration-Resistant Prostate Cancer Progressing After Docetaxel Treatment: A Randomised Open-Label Trial (2011) (5)
Prostate specific antigen doubling time (PSADT) predicts for distant failure and prostate cancer specific survival (PCSS) in men with biochemical relapse after radical prostatectomy (RP). (2004) (5)
Re: variation in continence and potency by definition. (2004) (5)
Fine-Mapping and Family-Based Association Analyses of Prostate Cancer Risk Variants at Xp11 (2009) (5)
Proscar and Propecia--a therapeutic perspective. (2005) (5)
A Prospective Study of Physical Activity and Incident and Fatal Prostate Cancer (2006) (5)
Calcium intake and prostate cancer risk in a long-term aging study: The Baltimore Logitudinal Study of Aging. (2003) (5)
The impact of androgen deprivation on quality of life after radical prostatectomy for prostate carcinoma. (2003) (5)
Effects of hormones in the newborn period on the development of the penis. (1977) (5)
The binding of a potent synthetic androgen--methyltrienolone (R 1881)--to cytosol preparations of human prostatic cancer. (1977) (5)
The Heterogeneity of Benign Prostatic Hyperplasia (1993) (5)
Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial. (2005) (5)
290 CAN WE STOP PSA TESTING 10 YEARS AFTER RADICAL PROSTATECTOMY (2010) (5)
Anatomical considerations in suprahilar lymph node dissection for testicular tumors. (1981) (5)
Screening by prostate-specific antigen and digital rectal examination in relation to prostate cancer mortality. A case-control study. (2005) (5)
Re: Surrogate endpoints for prostate cancer-specific mortality after radiotherapy and androgen suppression therapy in men with localised or locally advanced prostate cancer: an analysis of two randomised trials. (2012) (4)
Determining Cause of Death in Prostate Cancer: Are Death Certificates Valid? (2002) (4)
Rapid development of carcinoma in diverticulum of the bladder. A pitfall in conservative management. (1973) (4)
Immediate Adjuvant Radiation Therapy Following Radical Prostatectomy Should Not Be Advised for Men with Extraprostatic Extension Who Have Negative Surgical Margins. (2016) (4)
Seminomas Complicating Undescended Intraabdominal Testes in Patients With Prior Negative Findings From Surgical Exploration (1999) (4)
Experimental cryptorchism: Effect on serum LH and FSH in the rat (2004) (4)
Re: The Prostate Cancer Prevention Trial: design, biases and interpretation of study results. P. J. Goodman, I. M. Thompson, Jr., C. M. Tangen, J. J. Crowley, L. G. Ford and C. A. Coltman, Jr., J Urol, 175: 2234-2242, 2006. (2006) (4)
Re: Long-term effects of finasteride on prostate specific antigen levels: results from the Prostate Cancer Prevention Trial. (2006) (4)
LONG-TERM SURVIVAL AFTER RADICAL PROSTATECTOMY FOR MEN WITH HIGH PATHOLOGIC GLEASON SUM (2009) (4)
MRI and ultrasonography in staging prostate cancer (Reply) (1991) (4)
Re: Effect of treatment with 5-α reductase inhibitors on progression in monitored men with favourable-risk prostate cancer. (2012) (4)
VALIDATION OF THE PARTIN TABLES FOR PREDICTING PATHOLOGIC STAGE OF CLINICALLY CONFINED PROSTATE CANCER (1999) (4)
Re: Potency-sparing radical retropubic prostatectomy: a simplified anatomical approach. (1996) (4)
Renovascular hypertension: results of medical and surgical therapy. (1981) (4)
Ultrasonography of prostatic carcinoma employing amplitude‐enveloped (AM) and frequency‐demodulated (FM) imaging: in vivo, in vitro, and pathologic correlation. (1986) (4)
2151 ASSOCIATION OF PROSTATE CANCER RISK SNPS WITH AGE AT TREATMENT: POTENTIAL FOR PREDICTION OF EARLY ONSET OF DISEASE (2010) (4)
How Surgical Innovation Reduced Death and Suffering From Prostate Cancer (2013) (4)
Re: vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). (2012) (4)
Stereotactic ablative radiation therapy for the treatment of oligometastatic prostate cancer. (2017) (3)
Predicting Pathological Stage of Localized Prostate Cancer-Reply (1997) (3)
Re: Association of clinical benign prostate hyperplasia with prostate cancer incidence and mortality revisited: a nationwide cohort study of 3,009,258 men. (2012) (3)
1023: Inguinal Hernia Repair at the Time of Radical Retropubic Prostatectomy (2005) (3)
Efficacy and Safety Profile of Long-Term Nitrofurantoin in Urinary Infections: 18 Years' Experience (1999) (3)
Major postoperative complications secondary to use of the Bookwalter self-retaining retractor. (2003) (3)
1135: Who Dies from Prostate Cancer after Radical Prostatectomy? Influence of Post-Operative Prostate Specific Antigen Doubling Time, Pathological Gleason Sum, and Time from Surgery to Biochemical Recurrence (2005) (3)
Re: Screening for prostate cancer: a review of the evidence for the U.S. Preventive Services Task Force. (2012) (3)
Re: GSK Statement on Avodart™ (Dutasteride) for Prostate Cancer Risk Reduction (2011) (3)
The Value of Prostatic Specific Antigen in the Management of Adenocarcinoma of the Prostate (1987) (3)
Nafarelin acetate and benign prostatic hyperplasia. (1988) (3)
744: Cancer Control Following Radical Prostatectomy in Men with Capsular Incision (2007) (3)
MOLECULAR STAGING OF MEN WITH SEMINAL VESICLE INVASION AND NEGATIVE LYMPH NODES AT RADICAL PROSTATECTOMY (1999) (3)
IMPACT OF SALVAGE ANDROGEN DEPRIVATION THERAPY ON OVERALL SURVIVAL IN MEN WITH BIOCHEMICAL RECURRENCE AFTER RADICAL PROSTATECTOMY (2009) (3)
BENIGN AND MALIGNANT NEOPLASMS OF PROSTATE (2000) (3)
Re: does perineural invasion on prostate biopsy predict adverse prostatectomy outcomes? (2011) (3)
Re: Radical prostatectomy versus observation for localized prostate cancer. (2012) (3)
Analysis of the defensin gene family for DNA sequence variants. (2002) (3)
327: Updated Recurrence-Free Survival (RFS) Prediction Model Following Radical Prostatectomy (RRP) (2007) (3)
Long Term-Survival after Radical Prostatectomy for men with High Gleason Sum. (2010) (3)
Trousseau's syndrome in a patient with metastatic prostate cancer. (2000) (3)
Investigation of human anti-mouse antibodies as potential cause of postprostatectomy PSA elevation. (2009) (3)
The value of prostate-specific antigen in the management of localized prostatic cancer. (1989) (3)
Re: Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. (2012) (3)
Re: The natural history of metastatic progression in men with prostate-specific antigen recurrence after radical prostatectomy: long-term follow-up. (2012) (3)
Sipuleucel-T immunotherapy for castration-resistant prostate cancer: Editorial comment (2011) (3)
Re: The Gleason Score of Tumor at the Margin in Radical Prostatectomy is Predictive of Biochemical Recurrence. (2011) (3)
Re: long-term quality of life outcome after proton beam monotherapy for localized prostate cancer. (2012) (2)
Acceptability and complications of prostate biopsy in population-based PSA screening versus routine clinical practice: a prospective, controlled study. (2003) (2)
Re: External Beam Radiotherapy for Prostate Cancer: Urinary Outcomes for Men With High International Prostate Symptom Scores (IPSS) (2011) (2)
RE: EDITORIAL COMMENT (1997) (2)
The role of radical prostatectomy in the management of stage B adenocarcinoma of the prostate. (1987) (2)
Estimated impact of the prostate cancer prevention trial on population mortality. (2005) (2)
Re: Radiation therapy after radical prostatectomy: impact on metastasis and survival S. A. Boorjian, R. J. Karnes, P. L. Crispen, L. J. Rangel, E. J. Bergstralh and M. L. Blute J Urol 2009; 182: 2708-2715. (2010) (2)
Comparison of the efficacy of local therapies for localized prostate cancer in the prostate-specific antigen era: a large single-institution experience with radical prostatectomy and external-beam radiation. (2003) (2)
Fine-Mapping and Family-Based Association Analyses of Prostate Cancer Risk Variants at Xp 11 (2009) (2)
Inhibition by antiandrogens of the prostatic growth stimulated by adrenal androgens and pituitary prolactin in castrate rats. (1969) (2)
Prostate cancer kills (1995) (2)
Alcohol consumption and risk of prostate cancer in middle-aged men. (2005) (2)
Re: Ultrasensitive serum prostate specific antigen nadir accurately predicts the risk of early relapse after radical prostatectomy. (2005) (2)
Conflict of interest or widely held misconception? (1998) (2)
Re: Risk Profiles and Treatment Patterns Among Men Diagnosed as Having Prostate Cancer and a Prostate-Specific Antigen Level Below 4.0 ng/ml. (2011) (2)
DIGITAL RECTAL EXAMINATION AND IMAGING STUDIES ARE UNNECESSARY IN MEN WITH AN UNDETECTABLE PSA FOLLOWING RADICAL PROSTATECTOMY (1999) (2)
Cavernous nerve grafts to restore erectile function in a rat model (1989) (2)
Re: Abiraterone and increased survival in metastatic prostate cancer. (2011) (2)
External Beam Radiation Therapy After Radical Prostatectomy: Efficacy and Impact on Urinary Continence (2005) (2)
Percutaneous antegrade pyelography in hydronephrosis. Preoperative assessment. (1973) (2)
Re: Prostate-specific antigen concentration in young men: new estimates and review of the literature. (2012) (2)
Urological Oncology: Prostate Cancer. (2007) (2)
Re: regulator sues pomegranate juice maker. (2011) (2)
Evidence for a general cancer susceptibility locus at 3p24 in families with hereditary prostate cancer. (2005) (2)
Race/Ethnicity and the Intensity of Medical Monitoring Under ‘Watchful Waiting’ for Prostate Cancer (2004) (2)
Re: Focal therapy for localised unifocal and multifocal prostate cancer: a prospective development study. (2012) (2)
Re: Germline mutations in HOXB13 and prostate cancer risk. (2012) (2)
Re: Prostate-specific antigen velocity (PSAV) risk count improves the specificity of screening for clinically significant prostate cancer. (2012) (2)
Re: Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. (2011) (2)
1582: Who is Cured? How Long after Radical Prostatectomy Can PSA Rise? (2006) (2)
Editorial: Localized Prostate Cancer-Mortality and Morbidity (1997) (2)
Re: Genetic Correction of PSA Values Using Sequence Variants Associated With PSA Levels (2011) (2)
Salvage Radiotherapy for Recurrent Prostate Cancer After Radical Prostatectomy (2004) (2)
Re: How Charles Huggins Made His Nobel Prize Winning Discovery—in His Own Words: An Historic Audio Recording (2012) (1)
CHEK2 MUTATIONS INCREASE RISK FOR PROSTATE CANCER BUT DO NOT DIFFERENTIATE RISK OF LETHAL FROM INDOLENT DISEASE: PD37‐11 (2017) (1)
If You Want to Make an Important Discovery, Listen to Your Patients. (2017) (1)
Re: Quality of Life (1996) (1)
MP62-13 ASSOCIATION OF PROSTATE CANCER POLYGENIC RISK SCORE WITH NUMBER AND LATERALITY OF TUMOR CORES IN ACTIVE SURVEILLANCE PATIENTS (2021) (1)
Cryptorchism: effect on pituitary gonadotropin secretion in the rat. (1970) (1)
Is PSA velocity a marker of prostate cancer stage (1996) (1)
COMMENT ON: DISEASE PROGRESSION FOLLOWING RADICAL PROSTATECTOMY IN MEN WITH GLEASON SCORE 7 TUMOR. AUTHORS' REPLY (1999) (1)
Radical prostatectomy: Expanding role in the management of patients with adenocarcinoma of the prostate (1990) (1)
Association of variants at two 17q loci with prostate cancer risk in European and African Americans (2011) (1)
Re: Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. (2012) (1)
GERMLINE MUTATIONS IN DNA REPAIR GENES ARE SIGNIFICANTLY ENRICHED IN LETHAL PROSTATE CANCER AND ARE ASSOCIATED WITH DISEASE SURVIVAL: MP57‐01 (2017) (1)
384: Prognostic Significance of Gleason Grade Discrepancies between Needle Biopsy and Radical Prostatectomy (2007) (1)
995 ALLOGENEIC BLOOD TRANSFUSION IS AN INDEPENDENT PREDICTOR OF OVERALL SURVIVAL AFTER RADICAL PROSTATECTOMY (2013) (1)
332: Updated Nomogram to Predict Pathologic stage of Prostate Cancer Given PSA, Clinical stage, and Biopsy Gleason Score (Partin Tables) Based on Cases From 2000-2005 (2007) (1)
CLINICAL UROLOGY: Letters to the EditorRE: RADICAL PROSTATECTOMY FOR LOCALIZED PROSTATE CANCER PROVIDES DURABLE CANCER CONTROL WITH EXCELLENT QUALITY OF LIFE: A STRUCTURED DEBATE (2001) (1)
The Effect of Nafarelin Acetate, a Luteinizing-Hormone-Releasing Hormone Agonist, on Benign Prostatic Hyperplasia (1988) (1)
Impact of Neoadjuvant Androgen Ablation and Other Factors on Late Toxicity After External Beam Prostate Radiotherapy (2004) (1)
Re: Physical Activity and Survival After Prostate Cancer Diagnosis in the Health Professionals Follow-Up Study (2011) (1)
Re: Usefulness of prostate-specific antigen (PSA) rise as a marker of prostate cancer in men treated with dutasteride: lessons from the REDUCE study. (2012) (1)
SIGNIFICANCE OF PRIOR NEGATIVE NEEDLE BIOPSIES IN MEN SUBSEQUENTLY DIAGNOSED WITH PROSTATE CANCER (1999) (1)
LOCAL RECURRENCE AND SURVIVAL FOLLOWING NERVE SPARING FOLLOWUP RADICAL CYSTOPROSTATECTOMY FOR BLADDER CANCER: 1O-YEAR (1996) (1)
289 ANATOMICAL EXTENT OF LYMPH NODE DISSECTION: IMPACT ON MEN WITH POSITIVE LYMPH NODES AT TIME OF RADICAL PROSTATECTOMY (2011) (1)
Serum proteomic patterns for detection of prostate cancer. (2003) (1)
Re: breast and prostate cancer: familial associations. (2011) (1)
Postoperative radiotherapy in 423 patients with pT30NO prostate cancer. (2003) (1)
Re: perineural invasion predicts increased recurrence, metastasis, and death from prostate cancer following treatment with dose-escalated radiation therapy. (2012) (1)
725: Radical Prostatectomy for Clinical Stage T3 Disease (2007) (1)
Identification of a major susceptibility locus for human prostate cancer (1997) (1)
Lack of evidence for aromatase in human prostatic tissues: Effects of 4-hydroxyandrostenedione and other inhibitors on androgen metabolism: Editorial comment (1990) (1)
Computerized tomography and lymphangiography in staging testis tumors. (1982) (1)
Re: A novel two-stage, transdisciplinary study identifies digoxin as a possible drug for prostate cancer treatment. (2012) (1)
Re: Effect of dutasteride on prostate biopsy rates and the diagnosis of prostate cancer in men with lower urinary tract symptoms and enlarged prostates in the combination of avodart and tamsulosin trial. (2011) (1)
Re: Comorbidity and mortality results from a randomized prostate cancer screening trial. (2011) (1)
Risk-AssociatedVariants onClinicopathologic Variables in 5 , 895 ProstateCancer Patients (2009) (1)
Re: Editorial Comment on Focal Therapy for Localised Unifocal and Multifocal Prostate Cancer: A Prospective Development Study (Lancet Oncol 2012; 13: 622- 632) (2012) (1)
Re: Increased Cancer Risks for Relatives of Very Early-Onset Breast Cancer Cases With and Without BRCA1 and BRCA2 Mutations. (2011) (1)
Extraperitoneal standard laparoscopic radical prostatectomy. (2005) (1)
Re: Primary Care Providers' Response to the US Preventive Services Task Force Draft Recommendations on Screening for Prostate Cancer (2012) (1)
Re: years of potential life lost caused by prostate cancer deaths in the United States-projection from 2004 through 2050. (2011) (1)
Joseph J. Kaufman: renaissance man. (2015) (1)
Re: Radical prostatectomy versus watchful waiting in early prostate cancer. (2011) (1)
PROSTATE CANCER-SPECIFIC SURVIVAL FOLLOWING SALVAGE RADIOTHERAPY VS. OBSERVATION IN MEN WITH BIOCHEMICAL RECURRENCE AFTER RADICAL PROSTATECTOMY (2008) (1)
SIGNIFICANCE OF PREOPERATIVE PSA VELOCITY (PSAV) IN MEN WITH LOW SERUM PSA AND NORMAL DRE (2008) (1)
Re: Active Surveillance Program for Prostate Cancer: An Update of The Johns Hopkins Experience (2011) (1)
Re: Lih-Ming Wong, Neil Fleshner, Antonio Finelli. Impact of 5-alpha reductase inhibitors on men followed by active surveillance for prostate cancer: a Time-dependent covariate reanalysis. Eur Urol 2013;64:343. (2013) (1)
POD-02.10: Individual and Cumulative Effect of Prostate Cancer Risk-associated Variants on Clinicopathologic Variables in 5,895 Prostate Cancer Patients (2009) (1)
Book Review Do No Harm: How a Magic Bullet for Prostate Cancer Became a Medical Quandary By Stewart Justman. 236 pp. Chicago, Ivan R. Dee, 2008. $26. 978-1-56663-627-8 (2008) (1)
POD-05.08: Predicting the Long-Term Risk of Prostate Cancer-Specific Mortality After Radical Prostatectomy (2009) (1)
Large-scale randomized prostate cancer screening trials: program performance in the European Randomized Screening for Prostate Cancer trial and the Prostate, Lung, Colorectal and Ovary Cancer Trial. (2002) (1)
Differences in inherited risk among relatives of hereditary prostate cancer patients using genetic risk score (2018) (1)
Response to letter to Editor from Lawrence Klotz re my Editorial Comment on Focal Therapy for Localised Unifocal and Multifocal Prostate Cancer: A Prospective Development Study. (2012) (1)
Combined hormone control therapy and radical prostatectomy in the treatment of selected cases of advanced carcinoma of the prostate: A retrospective study based upon 25 years of experience: Editorial comment (1990) (1)
Re: contemporary experience with ketoconazole in patients with metastatic castration-resistant prostate cancer: clinical factors associated with PSA response and disease progression. (2012) (1)
Re: Randomized, prospective, controlled study comparing radical prostatectomy alone and neoadjuvant androgen withdrawal in the treatment of localized prostate cancer. (1997) (1)
Oxidative DNA damage in prostate cancer patients consuming tomato sauce-based entrees as a whole-food intervention. (2002) (1)
Re: Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial. (2012) (1)
PROSTATE-SPECIFIC ANTIGEN DOUBLING TIME (PSADT), GLEASON SCORE AND THE TIME TO PSA RECURRENCE FOLLOWING RADICAL PROSTATECTOMY PREDICTS TIME TO DISTANT PROGRESSION (1999) (1)
Re.: Suicide risk in men with prostate-specific antigen-detected early prostate cancer: a nationwide population-based cohort study from PCBaSe Sweden. (2011) (1)
726: Death in Patients with Recurrent Prostate Cancer after Radical Prostatectomy: PSADT Subgroups and Their Associated Contributions to All-Cause Mortality (2007) (1)
Adult UrologyUrological Survey: Urological Oncology: Prostate CancerRe: Germline BRCA Mutations are Associated with Higher Risk of Nodal Involvement, Distant Metastasis, and Poor Survival Outcomes in Prostate Cancer (2013) (1)
Factors influencing prostate cancer specific mortality in patients receiving delayed androgen deprivation therapy for metastasis after biochemical recurrence following radical prostatectomy. (2006) (1)
1191: Survival Following Hormonal Therapy: Men who Develop Metastasis More than Five Years Following Radical Prostatectomy Live Longer (2006) (1)
Validation of prostate cancer risk-related loci identified from genome-wide association studies using family-based association analysis: evidence from the International Consortium for Prostate Cancer Genetics (ICPCG) (2011) (1)
Associated with Prostate Cancer Risk-Methylacyl-CoA Racemase Are α Sequence Variants of Updated Version (2002) (1)
Re: The Prognostic Significance of Capsular Incision Into Tumor During Radical Prostatectomy (2011) (1)
Researchers The NCCN Prostate Cancer Clinical Practice Guidelines in OncologyTM (2010) (1)
Re: Mortality Results From the Göteborg Randomised Population-Based Prostate-Cancer Screening Trial (2011) (1)
Re: FDA panel votes against drugs said to prevent prostate cancer. (2011) (1)
PSA KINETICS ALONE ARE AN UNRELIABLE TRIGGER FOR INTERVENTION IN A PROSTATE CANCER SURVEILLANCE PROGRAM (2009) (1)
474: Pathologic Outcomes and Biochemical Progression in Men with T1C Prostate Cancer Undergoing Radical Prostatectomy with PSA 2.6-4.0 ng/ml Versus PSA 4.1-6.0 ng/ml (2006) (1)
Re: Smoking and prostate cancer survival and recurrence. (2012) (1)
PROGRESSION OUTCOMES AFTER RADICAL PROSTATECTOMY FOR MEN IN THEIR 30'S COMPARED TO OLDER MEN (2008) (1)
Quinacrine fluorescence of testicular tumors. (1973) (1)
Re: Prostate-specific antigen screening trials and prostate cancer deaths: the androgen deprivation connection. (2014) (1)
Impact of postoperative prostate‐specific antigen disease recurrence and the use of salvage therapy on the risk of death (2011) (1)
Predicting prostate cancer specific mortality following biochemical recurrence after radical prostatectomy (2005) (0)
RE: Prostate specific antigen after gonadal androgen withdrawal and deferred flutamide treatment. (1996) (0)
Re: Knowledge and Use of Finasteride for the Prevention of Prostate Cancer (2011) (0)
In Reply: Re: Editorial Comment (1997) (0)
Letters to the EditorRE: RADIOTHERAPY FOR ISOLATED SERUM PROSTATE SPECIFIC ANTIGEN ELEVATION AFTER PROSTATECTOMY FOR PROSTATE CANCER (2000) (0)
Re: prediction of erectile function following treatment for prostate cancer. (2012) (0)
Early age at diagnosis in families providing evidence of linkage to the hereditary prostate cancer locus (HPC1) on chromosome 1. (1998) (0)
Localized prostate cancer-mortality and morbidity. (1997) (0)
Prostate Health Council. (1991) (0)
SURVIVAL OUTCOMES IN SEPTUAGENARIANS AND OCTOGENARIANS AFTER RADICAL PROSTATECTOMY (2009) (0)
Re.: Interval cancers in the Antwerp European Randomised Study of Screening for Prostate Cancer study, using a 6 year screening interval. (2011) (0)
Association of rare, recurrent nonsynonymous variants in the germline of prostate cancer patients of African ancestry (2022) (0)
Re: An Empirical Evaluation of Guidelines on Prostate-Specific Antigen Velocity in Prostate Cancer Detection (2011) (0)
In Reply: Clinical and Biological Characteristics of Familial Benign Prostatic Hyperplasia (1997) (0)
613: Natural History of Organ-Confined, Gleason ≤6 Prostate Cancer Following Radical Prostatectomy (RP) (2007) (0)
Re: Long-term projections of the harm-benefit trade-off in prostate cancer screening are more favorable than previous short-term estimates. (2012) (0)
Prostate cancer screening and mortality: a case-control study (United States). (2005) (0)
A multicenter, double-blind, placebo-controlled trial of the efficacy of prazosin in the treatment of dysuria associated with benign prostatic hypertrophy: Editorial comment (1990) (0)
Re: impact of meat consumption, preparation, and mutagens on aggressive prostate cancer. (2012) (0)
Self-retaining intraurethral stent: An alternative to long-term indwelling catheters or surgery in the treatment of prostatism: Editorial comment (1990) (0)
Editorial Comment: This study, which was carried out in the pre-PSA era, demonstrates that patients who underwent a digital rectal examination had a 40% reduction in prostate cancer mortality (OR 0.60, 95% CI 0.38 to 0.93). (2004) (0)
AB68. Novel regulators of testosterone production (2014) (0)
Critical evaluation of transurethral resection and incision of the prostate: Editorial comment (1990) (0)
Campbell's urology, study guide (1998) (0)
COMMENT ON: PROSTATE SPECIFIC ANTIGEN AFTER GONADAL ANDROGEN WITHDRAWAL AND DEFERRED FLUTAMIDE TREATMENT. AUTHOR'S REPLY (1996) (0)
PD52-04 RARE GERMLINE PATHOGENIC MUTATIONS OF DNA REPAIR GENES ARE MOST STRONGLY ASSOCIATED WITH GRADE GROUP 5 PROSTATE CANCER (2020) (0)
843: Early Alterations in Nuclear Structure of Normal Appearing Prostate Epithelium in a Cancerous Prostate Predict Bone Metastasis Following Biochemical Recurrence (2004) (0)
Editorial Comment: Although this is a small study, the results are reassuring. Medical man- agement of BPH does not appear to affect adversely free to total serum PSA levels. (1997) (0)
Proc. V Int. Congr. Endocrinology, Vol. II: Current concepts (1977) (0)
Laparoscopic radical prostatectomy: is intact organ removal attainable? Study of margin status. (2005) (0)
Fatigue in prostate cancer survivors treated with definitive radiotherapy and LHRH analogs: Editorial comment (2011) (0)
Ultrasonically guided 125Iodine seed implantation with external radiation in management of localized prostatic carcinoma: Editorial comment (1990) (0)
Re: Risk of Colorectal Cancer in Men on Long-Term Androgen Deprivation Therapy for Prostate Cancer (2011) (0)
Dynamic contrast-enhanced CT for prostate cancer: Relationship between image noise, voxel size, and repeatability (2011) (0)
224: Msrl Mutants Implicated in Prostate Cancer Risk Encode Non-Functional Proteins (2005) (0)
Original Articles BIOLOGICAL AGGRESSIVENESS OF HEREDITARY PROSTATE CANCER: LONG-TERM EVALUATION FOLLOWING RADICAL PROSTATECTOMY (1998) (0)
Re: “How hugh hampton young's treatment of president woodrow wilson's urinary retention and urosepsis affected the resolution of world war I,” fogg R, kutikov A, usso RG, canter D, J urol 2011;186(3):1153 (2013) (0)
Utility of the Prostate-specific Antigen Test (1994) (0)
Genome-wide association of familial prostate cancer cases identifies evidence for a rare segregating haplotype at 8q24.21 (2016) (0)
Do Younger Men Have Better Biochemical Outcomes After Radical Prostatectomy (2004) (0)
RE: EDITORIAL COMMENT: TAKING ON PROSTATE CANCER (1997) (0)
Results of a Randomized, Population-Based Study of Biennial Screening Using Serum Prostate-Specific Antigen Measurement to Detect Prostate Carcinoma (2004) (0)
Khan MA, Walsh PC, Miller MC, et al. Quantitative alterations in nuclear structure predict prostate carcinoma distant metastasis and death in men with biochemical recurrence after radical prostatectomy. Cancer. (2003) 98(12):2583–91. (2004) (0)
Re: orgasm-associated urinary incontinence and sexual life after radical prostatectomy. (2012) (0)
Re: the relationship between prostate-specific antigen and prostate cancer risk: the prostate biopsy collaborative group. (2011) (0)
Comment on: A Randomized Trial of Radical Radiotherapy for the Management of pTlG3 NXMO Transitional Cell Carcinoma of the Bladder. Authors' reply (2008) (0)
Guest editorial: Prostate health council (1991) (0)
2137 THE PREVALENCE OF THE HOXB13 GLY84GLU PROSTATE CANCER RISK ALLELE IN MEN TREATED WITH RADICAL PROSTATECTOMY (2013) (0)
822: The Influence of Recurrent Prostate Cancer on Serum Testosterone Levels (2005) (0)
Urological SurveyUROLOGICAL SURVEY (1998) (0)
Monotherapy for Stage T1–T2 Prostate Cancer: Radical Prostatectomy, External Beam Radiotherapy, or Permanent Seed Implantation (2005) (0)
Obesity and the Risk of Prostate Cancer (2005) (0)
Re: Prostate Specific Antigen after Gonadal Androgen Withdrawal and Deferred Flutamide Treatment (1996) (0)
Sexually Transmitted Diseases: A Physician Tells You What You Need to Know (1999) (0)
Androgen Receptor Assay in Human Prostate Cancer (1983) (0)
THE RELATIONSHIP BETWEEN PROSTATE VOLUME CHANGES AND PSA VELOCITY IN A LONGITUDINAL AGING STUDY (2008) (0)
Risk of positive margins and biochemical recurrence in relation to nerve-sparing radical prostatectomy. (2002) (0)
Re: An analysis of whether higher health care spending in the United States versus Europe is 'worth it' in the case of cancer. (2012) (0)
Radiotherapy In The Definitive Management Of Oligometastatic Prostate Cancer (2019) (0)
933 PSA FREE OUTCOMES AFTER RADICAL PROSTATECTOMY AMONG MEN INITIALLY MANAGED WITH ACTIVE SURVEILLANCE FOR PROSTATE CANCER: JOHNS HOPKINS EXPERIENCE (2010) (0)
PLOIDY ANALYSIS AS A PREDICTOR OF RADICAL PROSTATECTOMY FOR STAGE T2 DISEASE (1995) (0)
UROLOGY FOUNDED IN 1917 BY HUGH HAMPTON YOUN G (1990) (0)
Ambiguous genitalia in a child. (1979) (0)
Survival Patterns for the Top Four Cancers in Canada: The Effects of Age, Region and Period (2006) (0)
1601: Different Gleason Scores in the Same Lobe: A Novel New Marker to Predict Side-Specific Extraprostatic Extension in Prostate Cancer Patients with Biopsy Gleason 7 or Higher (2005) (0)
Re: stepwise approach for nerve sparing without countertraction during robot-assisted radical prostatectomy: technique and outcomes. (2012) (0)
675: Body Mass Index and Outcomes in African-American and Caucasian Men Following Radical Prostatectomy for Clinically Localized Prostate Cancer (2005) (0)
MP01-13 E-CIGARETTE VAPOR EXPOSURE NEGATIVELY AFFECTS SPERMATOGENESIS IN MICE (2023) (0)
Re: Is Residual Neurovascular Tissue on Prostatectomy Specimens Associated With Surgeon Intent at Nerve-Sparing and Postoperative Quality of Life Measures? (2011) (0)
Re: Salvage radiation in men after prostate-specific antigen failure and the risk of death. (2011) (0)
No association between germline sequence variants in angiopoeitin-2 gene and prostate cancer risk (2002) (0)
Variable Definitions Influence the Reporting of Biochemical Failure Rates (2005) (0)
Treatments for Prostate Cancer in Older Men: 1984–1997 (2002) (0)
Re: Association of Treatment with 5α-Reductase inhibitors with Time to Diagnosis and Mortality in Prostate Cancer. (2019) (0)
Review and synopsis of: Radical prostatectomy for clinical stage T3a disease (2007) (0)
Clinical conferences at the Johns Hopkins Hospital. Prostatic carcinoma. (1978) (0)
Re: Quality of life: radical prostatectomy versus radiation therapy for prostate cancer. (1996) (0)
394: Overall Survival of men Undergoing Radical Prostatectomy (2007) (0)
1412: Impact of Delayed Intervention after Radical Prostatectomy on Cancer Control in Patients with High-Risk, Locally Advanced Adenocarcinoma of the Prostate (2007) (0)
Contents, Vol. 36, 1981 (1981) (0)
RE: Risk of Prostate Cancer in Men Treated With 5α-Reductase Inhibitors-A Large Population-Based Prospective Study. (2018) (0)
Is prostate cancer screening analogous to lung cancer screening? (1997) (0)
25 Estrogen binding I human prostate (1983) (0)
Re: comparative risk-adjusted mortality outcomes after primary surgery, radiotherapy, or androgen-deprivation therapy for localized prostate cancer. (2011) (0)
1638 EFFECTS OF 5-ALPHA REDUCTASE INHIBITOR USE IN MONITORED MEN WITH VERY-LOW RISK PROSTATE CANCER (2011) (0)
Re: It's time to abandon an upper limit of normal for prostate specific antigen: assessing the risk of prostate cancer: I. M. Thompson, D. P. Ankerst, R. Etzioni and T. Wang J Urol 2008; 180: 1219-1222. (2009) (0)
Can PSA testing stop 10 years after radical prostatectomy? (2011) (0)
1951 PELVIC LYMPH NODE DISSECTION IS ASSOCIATED WITH VENOUS THROMBOEMBOLISM RISK DURING LAPAROSCOPIC RADICAL PROSTATECTOMY (2010) (0)
Flutamide in treatment of benign prostatic hypertrophy: Editorial comment (1990) (0)
In Reply: Re (1997) (0)
Bowel complications after radiotherapy for carcinoma of the prostate: The volume effect: Editorial comment (1990) (0)
Re: Battling Prostate Cancer With 5-Alpha-Reductase Inhibitors: A Pyrrhic Victory? (2011) (0)
354 OBESITY AND LONG TERM SURVIVALS AFTER RADICAL PROSTATECTOMY IN A SINGLE TERTIARY REFERRAL CENTER (2013) (0)
UROLOGICAL ONCOLOGY: PROSTATE CANCER Residential Sunlight Exposure is Associated With a Decreased Risk of Prostate Cancer (2005) (0)
Residential sunlight exposure is associated with a decreased risk of prostate cancer. (2005) (0)
What ’ s known on the subject ? and What does the study add ? (2013) (0)
Re: Coffee Consumption and Prostate Cancer Risk and Progression in the Health Professionals Follow-Up Study (2011) (0)
Prostate specific antigen and local recurrence after radical prostatectomy: Editorial comment (I) (1990) (0)
COMMENT ON: QUALITY FOR LIFE : RADICAL PROSTATECTOMY VERSUS RADIATION THERAPY FOR PROSTATE CANCER. AUTHORS' REPLY (1996) (0)
COMBINATION OF FIVE SNPs PREDICTS INDIVIDUAL RISK FOR PROSTATE CANCER (2008) (0)
Long-term experience with flutamide in patients with prostatic carcinoma: Editorial comment (1990) (0)
Prostatic complications of testosterone replacement therapy: Editorial comment (1990) (0)
Abstract 5324: ERG expression and PTEN loss by BMI and weight change in men with prostate cancer (2017) (0)
Altered cognitive function in men treated for prostate cancer with leutinizing hormone-releasing hormone analogues and cyproterone acetate: a randomized controlled study. (2003) (0)
257: Stronger Association between Obesity and Biochemical Progression Following Radical Prostatectomy over Time (2005) (0)
PD34-07 NATURAL HISTORY OF PROGRESSION TO PSA RECURRENCE AND METASASIS AMONG AT RISK MEN FOLLOWING RADICAL PROSTATECTOMY (2014) (0)
Re: Impact of Prostate Weight on Probability of Positive Surgical Margins in Patients With Low-Risk Prostate Cancer After Robotic-Assisted Laparoscopic Radical Prostatectomy (2011) (0)
Impact of Intraoperative Edema During Transperineal Permanent Prostate Brachytherapy on Computer-Optimized and Preimplant Planning Techniques (2004) (0)
Re: EPCA-2: a highly specific serum marker for prostate cancer. (2012) (0)
The Classification and Prognosis of Untreated Stage A1 and A2 Prostate Cancer with a Comparison of their Histologic Findings at Radical Prostatectomy (1988) (0)
Re: Projecting prostate cancer mortality in the PCPT and REDUCE chemoprevention trials. (2012) (0)
Hormonal therapy of prostatic cancer. (1980) (0)
The Dual 5-Alpha-Reductase Inhibitor Dutasteride Induces Atrophic Changes and Decreases Relative Cancer Volume in Human Prostate (2005) (0)
Detection of prostate cancer with a blood-based assay for early prostate cancer antigen: Commentary (2006) (0)
Re: Disease-specific survival of men with prostate cancer detected during the screening interval: results of the European Randomized Study of Screening for Prostate Cancer-Rotterdam after 11 years of follow-up. (2011) (0)
Urological surveyUrological oncology: Prostate cancer (2006) (0)
PROSTATE SPECIFIC ANTIGEN TESTING AFTER RADICAL PROSTATECTOMY: CAN WE STOP AT 20 YEARS?: PD07‐09 (2017) (0)
Fatty Acid Synthase as a biomarker in prostate cancer: a high-throughput quantitative image analysis (2008) (0)
Re: should intervening benign tissue be included in the measurement of discontinuous foci of cancer on prostate needle biopsy? Correlation with radical prostatectomy findings. (2012) (0)
No differences in PSA failure rates following radical prostatectomy between men with pT2a AND pT2b tumors (2004) (0)
Re: suitability of PSA-detected localised prostate cancers for focal therapy: experience from the ProtecT study. (2012) (0)
Changes in Body Composition During Androgen Deprivation Therapy for Prostate Cancer (2002) (0)
Re: radiotherapy for isolated serum prostate specific antigen elevation after prostatectomy for prostate cancer. (2000) (0)
Re : The Relationship between the Extent of Extraprostatic Extension and Survival following Radical Prostatectomy (2015) (0)
Positive LymphNodes at Radical Prostatectomy : The JohnsHopkinsHospital 30-Year Experience (2013) (0)
299 A CONTEMPORARY ANALYSIS OF CLINICAL OUTCOMES FOR MEN WITH ADENOCARCINOMA OF THE PROSTATE WITH SEMINAL VESICLE INVASION (PT3B) AFTER RADICAL PROSATECTOMY (2010) (0)
Little or No Residual Prostate Cancer at Radical Prostatectomy: Vanishing Cancer or Switched Specimen? A Microsatellite Analysis of Specimen Identity (2005) (0)
Editorial Comments: Combination Finasteride and Flutamide in Advanced Carcinoma of the Prostate (1995) (0)
Finasteride reduced symptoms and need for surgery for benign prostatic hyperplasia (1998) (0)
SEGREGATION ANALYSIS OF SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA: NORTH AMERICAN FINASTERIDE TRIAL (1999) (0)
Comment on: the prostate cancer prevention trial : Design, biases and interpretation of study results. Author's reply (2006) (0)
PROSTATE CANCER KILLS. AUTHOR'S REPLY (1995) (0)
UROLOGICAL SURVEY: AbstractsBENIGN AND MALIGNANT NEOPLASMS OF PROSTATE (2000) (0)
Testosterone: effect on rat testis. (1972) (0)
Use of Transrectal Ultrasound to Stage Prostate Cancer-Reply (1994) (0)
Prostate-specific antigen (PSA) after anatomic radical retropubic prostatectomy: Long-term results in 1623 patients (1997) (0)
Genome-Wide LinkageAnalysis of 1 , 233 Prostate Cancer Pedigrees Fromthe International Consortium for ProstateCancerGeneticsUsingNovel sumLINKandsumLODAnalyses (2010) (0)
Prevalence of the HOXB 13 G 84 E prostate cancer risk allele in men treated with radical prostatectomy (2014) (0)
192 IMPLICATIONS OF SURGICAL MARGIN STATUS ON PROSTATE CANCER-SPECIFIC SURVIVAL (2011) (0)
Re: Trends in mortality from cancers of the breast, colon, prostate, esophagus, and stomach in East Asia: role of nutrition transition. (2012) (0)
767 PATHOLOGICAL AND ONCOLOGIC OUTCOMES FOR MEN WITH POSITIVE LYMPH NODES AT RADICAL PROSTATECTOMY: 30-YEAR EXPERIENCE FROM A SINGLE INSTITUTION (2012) (0)
Gleason Grade Remains an Important Prognostic Predictor in Men Diagnosed With Prostate Cancer While on Finasteride Therapy (2005) (0)
Distribution of PSA velocity by total PSA levels: Data from the Baltimore longitudinal study of aging: Editorial comment (2011) (0)
The natural history of progression to PSA recurrence and metastasis among at risk men following radical prostatectomy. (2014) (0)
Positive surgical margins at radical prostatectomy: Importance of the apical dissection: Editorial comment (I) (1990) (0)
Nerve Grafting and Radical Prostatectomy (2000) (0)
Re: outcomes in patients with Gleason score 8-10 prostate cancer: relation to preoperative PSA level. (2012) (0)
Mailed with this issue of the BJU International is a video presentation of the anatomical approach to radical retropubic prostatectomy (2004) (0)
Stat Bite: Family History and Risk of Prostate Cancer (1994) (0)
IS PROSTATE CANCER SCREENING ANALOGOUS TO LUNG CANCER SCREENING? AUTHOR'S REPLY (1997) (0)
Erectile function after prostate brachytherapy: Commentary (2006) (0)
Ejaculation Frequency and Subsequent Risk of Prostate Cancer (2004) (0)
Re.: Impact of common medications on serum total prostate-specific antigen levels: analysis of the National Health and Nutrition Examination Survey. (2011) (0)
Ten-year disease free survival after transperineal sonography-guided iodine-125 brachytherapy with or without 45-gray external beam irradiation in the treatment of patients with clinically localized, low to high gleason grade prostate carcinoma. (1999) (0)
In Honor of Hugh Judge Jewett (1988) (0)
Re: Immunohistochemical Study of the Cavernous Nerves in the Periprostatic Region (2011) (0)
Re: The Risks and Benefits of 5α-Reductase Inhibitors for Prostate-Cancer Prevention (2011) (0)
Aortography in Experimental Renal Failure (1971) (0)
Abstract 883: Weight gain is associated with an increased risk of prostate cancer recurrence in the PSA era (2010) (0)
379: A Critical Analysis of the Interpretation of Biochemical Recurrence in Surgically Treated Patients using the Revised ASTRO Criterion–"NADIR +2" (2007) (0)
Prognosis in stage D-1 prostate cancer relative to anatomic sites of nodal metastases: Editorial comment (1990) (0)
Ten-Year Survival in Patients With Metastatic Prostate Cancer (2005) (0)
IS BODY MASS INDEX ASSOCIATED WITH PROSTATE CANCER AGGRESSIVENESS? DATA FROM THE BALTIMORE LONGITUDINAL STUDY OF AGING (2009) (0)
Gay Men and Prostate Cancer: Invisible Diversity (2005) (0)
Symptoms and signs of prostatism as risk factors for prostatectomy: Editorial comment (1990) (0)
Re: One Man at a Time—Resolving the PSA Controversy (2012) (0)
Substratification of stage T1c prostate cancer based on the probability of biochemical recurrence. (2003) (0)
Editorial Comment: Radical Retropubic Prostatectomy (1995) (0)
Re: preoperative characteristics of men with unfavorable high-Gleason prostate cancer at radical prostatectomy. (2012) (0)
Prostate Cancer Screening. (2017) (0)
Re: Prostate Cancer Detection and Dutasteride: Utility and Limitations of Prostate-Specific Antigen in Men with Previous Negative Biopsies (2011) (0)
Re: Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer (2011) (0)
A Pitfall in Conservative Management (1973) (0)
401 UTILITY OF PSA VELOCITY FOR PREDICTION OF GLEASON SCORE UPGRADING BETWEEN BIOPSY AND RADICAL PROSTATECTOMY (2010) (0)
Preoperative PSA Level Significantly Associated With Interval to Biochemical Progression After Radical Retropubic Prostatectomy (2005) (0)
The antisteoporotic efficacy of intravenous pamidronate in men with prostate carcinoma receiving combined androgen blockade. A double blind, randomized, placebo-controlled crossover study. (2002) (0)
Abstract A96: The influence of infectious mononucleosis on prostate-specific antigen concentration as a marker of prostate involvement during infection (2011) (0)
Re: Disease-Free Survival Following Salvage Cryotherapy for Biopsy-Proven Radio-Recurrent Prostate Cancer (2011) (0)
Re: Urologists' self-referral for pathology of biopsy specimens linked to increased use and lower prostate cancer detection. (2012) (0)
Prostate carcinoma-current status and future direction. (1990) (0)
Germline mutations and sequence variants of the macrophage scavenger receptor 1 gene are associated with prostate cancer risk. (2002) (0)
A 66-year-old man with prostate-specific antigen recurrence and lung mass after radical prostatectomy. (2012) (0)
Acne in adolescence and cause-specific mortality: Lower coronary heart disease but higher prostate cancer mortality. The Glasgow alumni cohort study: Commentary (2006) (0)
2030 THE ADDED VALUE OF DIGITAL RECTAL EXAMINATION IN PROSTATE CANCER SCREENING AND OUTCOMES (2011) (0)
Re: radiotherapy and short-term androgen deprivation for localized prostate cancer. (2012) (0)
Urological Survey: Abstracts: Urological Oncology: Prostate CancerProstate-Specific Antigen and All-Cause Mortality: Results From the Baltimore Longitudinal Study on Aging (2004) (0)
Association analysis of 9,560 prostate cancer cases from the International Consortium of Prostate Cancer Genetics confirms the role of reported prostate cancer associated SNPs for familial disease (2013) (0)
RE: BIOLOGICAL AGGRESSIVENESS OF HEREDITARY PROSTATE CANCER (1999) (0)
2008 Best of the Rest in Urological Survey2008 Best of the Rest in Urological Survey (2008) (0)
305 EVOLUTION OF THE CLINICAL PRESENTATION OF MEN UNDERGOING RADICAL PROSTATECTOMY FOR HIGH-RISK PROSTATE CANCER (2011) (0)
PERIOPERATIVE COMPLICATIONS OF RADICAL PROSTATECTOMY (2008) (0)
Radioimmunoassay for prostatic acid phosphatase. (1980) (0)
V4-03 TECHNIQUE AND OUTCOMES OF BLADDER NECK INTUSSUSCEPTION DURING ROBOTIC-ASSISTED RADICAL PROSTATECTOMY: A PARALLEL COMPARATIVE TRIAL (2015) (0)
PREDICTING PATHOLOGICAL STAGE OF LOCALIZED PROSTATE CANCER. AUTHORS' REPLY (1997) (0)
Editorial Comment: Prostate cancer is a multifocal disease with an average of 7 separate tumors in a typical radical prostatectomy specimen. This study indicates that these tumors arise independently and do not represent intraglandular dissemination. (1998) (0)
AbstractsBenign and Malignant Neoplasms of the Prostate (1992) (0)
SAFETY AND FEASIBILITY OF NERVE-SPARING DURING RADICAL PROSTATECTOMY IN MEN WITH MULTIPLE BIOPSY CORES OF GLEASON 6 (2009) (0)
Re: Potency-Sparing Radical Retropubic Prostatectomy (1996) (0)
Survival in the prostate cancer prevention trial. (2013) (0)
Re: A population-based assessment of germline HOXB13 G84E mutation and prostate cancer risk. (2012) (0)
Re.: Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study. (2011) (0)
Re.: Association between glomerular filtration rate, free, total, and percent free prostate-specific antigen. (2011) (0)
Survival following early hormone therapy for men with rapid PSA doubling time within 2 years following radical prostatectomy. (2009) (0)
External beam radiotherapy for prostate cancer: Urinary outcomes for men with high International Prostate Symptom Scores (IPSS): Editorial comment (2011) (0)
Re: Antibiotics and Observation Have a Similar Impact on Asymptomatic Patients With a Raised PSA (2011) (0)
Re: Long-term results of an RTOG phase II trial (00-19) of external-beam radiation therapy combined with permanent source brachytherapy for intermediate-risk clinically localized adenocarcinoma of the prostate. (2012) (0)
The Prevalence and Nature of Orgasmic Dysfunction After Radical Prostatectomy (2005) (0)
Adult urologyUrological surveyUrological Oncology: Prostate Cancer (2006) (0)
IL2 The impact of surgical innovation on reducing death and suffering from prostate cancer (2011) (0)
Post-nerve-sparing prostatectomy, dose-escalated intensity-modulated radiotherapy: effect on erectile dysfunction. (2003) (0)
Lack of Prostate Cancer Radiosensitization by Androgen Deprivation (2002) (0)
367 LONG-TERM SURVIVAL OUTCOME IN MEN WITH FOCAL VERSUS ESTABLISHED EXTRAPROSTATIC EXTENSION IN A LARGE RADICAL PROSTATECTOMY SERIES (2013) (0)

This paper list is powered by the following services:

Other Resources About Patrick C. Walsh

en.wikipedia.org

What Schools Are Affiliated With Patrick C. Walsh?

Patrick C. Walsh is affiliated with the following schools: